Supplemental Online Content

Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 seroprevalence in the US as of September 2020. *JAMA Intern Med.* Published online November 24, 2020. doi:10.1001/jamainternmed.2020.7976

eMethods.
eFigure 1. Geographic distribution of serology specimens by county across 50 US states, Washington D.C., and Puerto Rico, July to September 2020
eFigure 2. Dates of sample collection for SARS-CoV-2 antibody testing in periods 1-4
eTable 1. Estimated number of infections based on period 1 seroprevalence estimates compared with the cumulative number of reported cases in each jurisdiction
eTable 2. Estimated number of infections based on period 4 seroprevalence estimates compared with the cumulative number of reported cases in each jurisdiction
eTable 3. Overall, sex-, age-, and metropolitan/nonmetropolitan-stratified SARS-CoV-2 prevalence estimates and 95% confidence intervals by jurisdiction during period 1
eTable 4. Overall, sex-, age-, and metropolitan/nonmetropolitan-stratified SARS-CoV-2 prevalence estimates and 95% confidence intervals by jurisdiction during period 2
eTable 5. Overall, sex-, age-, and metropolitan/nonmetropolitan-stratified SARS-CoV-2 prevalence estimates and 95% confidence intervals by jurisdiction during period 3
eTable 6. Overall, sex-, age-, and metropolitan/nonmetropolitan-stratified SARS-CoV-2 prevalence estimates and 95% confidence intervals by jurisdiction during period 4

This supplemental material has been provided by the authors to give readers additional information about their work.
eMethods

Introduction
This section details our analytic approach to the biweekly computation of weighted seroprevalence estimates for each jurisdiction accompanied by 95% confidence intervals. Our approach accounted for the variance due to sampling, weighting, and measurement error (sensitivity and specificity of the assay tests) and is based on an iterative poststratification process, also known as raking, that capitalizes on the American Community Survey (ACS) population data for each jurisdiction.¹

Weighting Process
Traditionally, probability sample surveys used to generate population estimates provide a probability of selection for each unit selected from the target population. These probabilities of selection are used to derive sampling weights to make representative population estimates. In this study, samples were generated through non-probability sampling (i.e., convenience sampling). Therefore, proper probabilities of selection could not be calculated.

There has been extensive recent research in the relative advantages and disadvantages of non-probability sampling. A comprehensive review is provided in an AAPOR Task Force Report.² This research has included alternative weighting approaches for non-probability samples ranging from simple post-stratification adjustments to more complex propensity matching.³⁵

In more recent comparisons, an iterative post-stratification method, or raking, has been recommended as an effective standard method.⁶⁻⁸ This approach is especially recommended when there is no parallel probability sample that can be used to calibrate the non-probability sample on many population dimensions and totals, commonly referred to as control totals. The raking approach allows the use of any number of population dimensions (e.g., demographic variable) without concern for small cell sizes associated with cross classification of multiple variables or variables with large numbers of levels (e.g., age categories × sex × race × income).

Raking Overview
The starting weights \( W_{jh}^0 \) are post-stratified by a factor \( F_{jh} \) for each respondent \( j \) within each level/cell \( h \) (e.g., age: 0-17) of a single demographic control total.

The adjustment factor is defined as:

\[
F_{jh} = \frac{T_h}{\sum W_{jh}^0}
\]

Where \( T_h \) is the population total within poststratification level/cell \( h \).

The post-stratified weight is then calculated as the product of the starting weight \( W_{jh}^0 \) and the poststratification factor within a level/cell \( F_{jh} \).

\[
W_{jh}^1 = W_{jh}^0 \times F_{jh}
\]

This process is repeated for each weighting dimension.
This process can be generalized as:

\[ F_{jh}^i = \frac{T_h}{\sum W_{jh}^i} \]

\[ W_{jh}^{i+1} = W_{jh}^i \times F_{jh}^i \]

Where, \( i \) signifies the current values of the raking procedure and \( i+1 \) signifies the values to be used in the next iteration.

As the post-stratification factor (\( F \)) for each demographic dimension is applied to the weights, the weighted totals for the previous demographic dimension will deviate from the population totals. However, as this post-stratification procedure is repeated, these deviations will tend to reduce to zero. Over many iterations, all the weighted demographic dimensions will match the demographic population totals (\( T \)).

This adjustment process is repeated until, \( F_{jh}^i \approx 1 \), signifying that the weights have converged and that the weighted sums will equal the population totals for all post-stratification dimensions.

**Raking Process**

We utilized the 2018 ACS 5-year population totals for age category and sex and 2013 Rural-Urban Continuum Codes for metropolitan and nonmetropolitan categories as raking dimensions. In order to avoid weighting cells that were too sparse or empty for many jurisdictions, we developed an approach to collapse cells which is described in the next section. The resulting weights adjusted for potential bias across age, sex, and metropolitan/nonmetropolitan categories.

For the raking process to converge in each raking stage, all data had to be non-missing for each raking dimension. If data were missing in proposed dimensions, we applied a combination of probabilistic imputation methods in order to arrive at a complete dataset.

**Cell Collapsing for Weighting**

In the following tables, we document the logical collapsing criteria used to ensure that each weighting cell had at least 2 observations prior to raking. The dark outlines correspond with the groups to be collapsed, which is also described in the “Collapsing Action” column.

For the age raking dimension, to maintain logical groupings across the age dimension, age groupings were collapsed upwards. The distinction between the <18 age group and other age groups was kept where possible.

| <18  | 18-49 | 50-64 | ≥65  | Collapsing Action          |
|------|-------|-------|------|-----------------------------|
| Filled | Filled | Filled | Filled | No collapsing               |
| **Sparse** | Filled | Filled | Filled | Collapse <18 and 18-49     |
| Filled | **Sparse** | Filled | Filled | Collapse 18-49 and 50-64   |
| Filled | Filled | **Sparse** | Filled | Collapse 50-64 and ≥65     |
| Filled | Filled | Filled | **Sparse** | Collapse 50-64 and ≥65   |
| Filled | Filled | **Sparse** | **Sparse** | Collapse 18-49, 50-64, and ≥65 |

© 2020 Bajema KL et al. *JAMA Internal Medicine*. 
For the sex raking dimension, if any cells were sparse both groups were collapsed.

| Male  | Female  | Collapsing Action          |
|-------|---------|-----------------------------|
| Filled| Filled  | No collapsing               |
| Filled| Sparse  | Collapse all sex groups    |
| Sparse| Filled  | Collapse all sex groups    |

For the metro raking dimension, if any cells were sparse both groups were collapsed.

| Non-Metro | Metro  | Collapsing Action          |
|-----------|--------|-----------------------------|
| Filled    | Filled | No collapsing               |
| Filled    | Sparse | Collapse all metro groups  |
| Sparse    | Filled | Collapse all metro groups  |

**Overview of Analysis Process**

We extended a previously used estimation approach in several ways, primarily to account for the sampling variability, and used weighted estimates adjusted to the population. In order to account for the variability associated with the measurement error (sensitivity and specificity), this adjustment process was performed within each bootstrap sample.

**Measurement Error Adjustment**

Each assay has a different sensitivity and specificity as defined by the manufacturer’s validation testing platform. The bootstrap loop performed a different adjustment for each type of antibody assay as outlined below:

1. Generate binomial probability distribution using sensitivity and specificity parameters provided by the lab as input;
2. By each age and sex group:
   a. Calculate unadjusted prevalence rates

© 2020 Bajema KL et al. *JAMA Internal Medicine.*
b. Using the sensitivity, specificity, and unadjusted prevalence rates, calculate a false positive rate and false negative rate.
c. Flip at random a proportion of positive and negatives cases corresponding to false positive and false negative rates.

Weighting
Our approach integrated the weighting into the bootstrap replications. With this approach, the raking process took place for each replicated bootstrap subsample together with the adjustments for sensitivity and specificity. In this way, the bootstrap replications accounted for all variability which was reflected in the empirical confidence intervals. This approach followed a similar bootstrapping variance estimation technique by Shao and Sitter’s method for variance estimation of imputed survey data.\textsuperscript{10}

Bootstrap Estimation
Through bootstrapping, we produced an adjusted prevalence estimate that incorporated both weighting and measurement error adjustments for 500 replicates. Then, drawing from the bootstrap distribution of all replicates, we calculated the point estimate from the mean and 95% confidence intervals from the 2.5\textsuperscript{th} and 97.5\textsuperscript{th} percentiles.

Number of Bootstrap Replications
We sought to empirically identify the ideal replicate sample size for the bootstrap estimation. Simulations were run to determine the optimal number of replications. Our simulation framework was to run 2,000 replicates and then draw subsamples of replicates with replacement for various replicate sizes, from 10 to 1,500.

Estimates were calculated for 49 jurisdictions with enough data at baseline. We calculated the standard error of the measurement adjusted jurisdiction total prevalence estimates at each replicate size, along with a comparison of each standard error to the standard errors of the full 2,000 replicate sample (assumed to be the “best” due to the largest sample size), which was defined as our benchmark.

On average, the largest deviance values across jurisdictions were from the 10-100 replicate size estimates. Decreases to the average standard error across jurisdictions was minimal after 400 replicates (see the following figure). Therefore, we chose 500 replicates.
Supplemental Figures

eFigure 1. Geographic distribution of serology specimens by county across 50 U.S. states, Washington D.C. and Puerto Rico, July to September 2020
eFigure 2. Dates of sample collection for SARS-CoV-2 antibody testing in periods 1-4\textsuperscript{a}

\textsuperscript{a}Period 1, July 27 to August 13, 2020; period 2, August 10 to 17, 2020; period 3, August 24 to September 10, 2020; period 4, September 8 to 24, 2020
### Supplemental Tables

eTable 1. Estimated number of infections based on period 1 seroprevalence estimates compared with the cumulative number of reported cases in each jurisdiction

| Jurisdiction | Reported Cases | Estimated Infections | Estimated Infections, Lower | Estimated Infections, Upper | Median Collection Date | Ratio of Estimated Infections to Reported Cases | Ratio Range |
|--------------|----------------|----------------------|-----------------------------|----------------------------|------------------------|-----------------------------------------------|-------------|
| AK           | 2,622          | 2,216                | 0                           | 8,271                      | 10-Aug                | 0.8                                           | 0.0-3.2     |
| AL           | 70,357         | 282,151              | 202,371                     | 375,067                    | 4-Aug                  | 4.0                                           | 2.9-5.3     |
| AR           | 34,655         | 122,618              | 81,944                      | 168,375                    | 4-Aug                  | 3.5                                           | 2.4-4.9     |
| AZ           | 152,944        | 569,628              | 285,509                     | 944,054                    | 6-Aug                  | 3.7                                           | 1.9-6.2     |
| CA           | 370,115        | 2,231,479            | 1,585,525                   | 3,041,859                  | 31-Jul                 | 6.0                                           | 4.3-8.2     |
| CO           | 39,344         | 132,747              | 49,227                      | 250,561                    | 31-Jul                 | 3.4                                           | 1.3-6.4     |
| CT           | 47,891         | 121,771              | 73,063                      | 169,047                    | 31-Jul                 | 2.5                                           | 1.5-3.5     |
| DC           | 11,649         | 26,695               | 14,922                      | 39,427                     | 6-Aug                  | 2.3                                           | 1.3-3.4     |
| DE           | 13,624         | 54,121               | 33,707                      | 78,048                     | 3-Aug                  | 4.0                                           | 2.5-5.7     |
| FL           | 360,394        | 885,720              | 570,568                     | 1,207,051                  | 3-Aug                  | 2.5                                           | 1.6-3.3     |
| GA           | 152,031        | 700,229              | 497,368                     | 907,208                    | 5-Aug                  | 4.6                                           | 3.3-6.0     |
| HI           | 1,488          | .                    | .                           | 6-Aug                      | .                      | .                                             | .           |
| IA           | 39,792         | 269,395              | 187,323                     | 355,225                    | 5-Aug                  | 6.8                                           | 4.7-8.9     |
| ID           | 18,694         | 75,901               | 30,381                      | 134,856                    | 10-Aug                 | 4.1                                           | 1.6-7.2     |
| IL           | 159,333        | 500,038              | 323,102                     | 668,000                    | 31-Jul                 | 3.1                                           | 2.0-4.2     |
| IN           | 59,600         | 146,023              | 73,012                      | 240,939                    | 6-Aug                  | 2.5                                           | 1.2-4.0     |
| KS           | 21,960         | 46,540               | 20,361                      | 81,446                     | 31-Jul                 | 2.1                                           | 0.9-3.7     |
| KY           | 23,414         | 106,565              | 58,611                      | 160,735                    | 3-Aug                  | 4.6                                           | 2.5-6.9     |
| LA           | 88,588         | 447,707              | 320,857                     | 573,158                    | 31-Jul                 | 5.1                                           | 3.6-6.5     |
| MA           | 112,879        | 286,868              | 197,393                     | 396,834                    | 31-Jul                 | 2.5                                           | 1.7-3.5     |
| MD           | 80,172         | 582,333              | 435,849                     | 772,642                    | 5-Aug                  | 7.3                                           | 5.4-9.6     |
| ME           | 3,723          | 6,664                | 0                           | 15,461                     | 5-Aug                  | 1.8                                           | 0.0-4.2     |
| MI           | 82,392         | 338,555              | 215,082                     | 481,942                    | 3-Aug                  | 4.1                                           | 2.6-5.8     |
| MN           | 48,679         | 193,458              | 113,864                     | 276,921                    | 6-Aug                  | 4.0                                           | 2.3-5.7     |
| MO           | 31,281         | 152,252              | 87,697                      | 219,851                    | 31-Jul                 | 4.9                                           | 2.8-7.0     |
| MS           | 47,071         | 212,202              | 112,079                     | 331,454                    | 5-Aug                  | 4.5                                           | 2.4-7.0     |
| MT           | 2,910          | 5,209                | 0                           | 17,397                     | 6-Aug                  | 1.8                                           | 0.0-6.0     |
| NC           | 95,478         | 253,891              | 133,039                     | 377,789                    | 31-Jul                 | 2.7                                           | 1.4-4.0     |
| ND           | 5,206          | 54,911               | 9,779                       | 107,414                    | 5-Aug                  | 10.5                                          | 1.9-20.6    |
| NE           | 22,717         | 140,952              | 100,000                     | 185,714                    | 3-Aug                  | 6.2                                           | 4.4-8.2     |
| NH           | 6,164          | 10,749               | 2,956                       | 19,886                     | 31-Jul                 | 1.7                                           | 0.5-3.2     |
| NJ           | 177,591        | 1,314,513            | 1,086,250                   | 1,560,540                  | 5-Aug                  | 7.4                                           | 6.1-8.8     |
| NM           | 16,456         | 41,849               | 22,808                      | 63,192                     | 31-Jul                 | 2.5                                           | 1.4-3.8     |
| State | Cases Reporting Week | NRR | Cases Reporting Jurisdiction | NRR | Cases Reporting Jurisdiction | NRR | Cases Reporting Jurisdiction | NRR | Cases Reporting Jurisdiction |
|-------|----------------------|-----|-----------------------------|-----|-----------------------------|-----|-----------------------------|-----|-----------------------------|
| NV    | 33,288               | 149,065 | 106,099                     | 194,662 | 31-Jul | 4.5 | 3.2-5.8                   |
| NY    | 408,945              | 4,571,100 | 3,937,424                   | 5,163,577 | 5-Aug | 11.2 | 9.6-12.6                 |
| OH    | 72,280               | 267,763  | 129,225                     | 420,272 | 31-Jul | 3.7 | 1.8-5.8                   |
| OK    | 24,139               | 62,690   | 33,304                      | 97,562  | 31-Jul | 2.6 | 1.4-4.0                   |
| OR    | 16,101               | 93,885   | 42,044                      | 156,747 | 7-Aug | 5.8 | 2.6-9.7                   |
| PA    | 104,358              | 1,304,700 | 730,376                     | 2,201,362 | 6-Aug | 12.5 | 7.0-21.1                 |
| PR    | .                    | 37,256   | 14,564                      | 60,965  | .     | .   | .                       |
| RI    | 17,291               | 31,698   | 12,996                      | 58,219  | 5-Aug | 1.8 | 0.8-3.4                   |
| SC    | 78,298               | 401,430  | 286,948                     | 529,788 | 7-Aug | 5.1 | 3.7-6.8                   |
| SD    | 8,075                | .        | .                           | 5-Aug   | .     | .   | .                       |
| TN    | 84,508               | 419,019  | 293,313                     | 548,715 | 5-Aug | 5.0 | 3.5-6.5                   |
| TX    | 311,606              | 1,645,227 | 1,126,562                   | 2,216,873 | 31-Jul | 5.3 | 3.6-7.1                   |
| UT    | 35,582               | 97,451   | 51,771                      | 153,181 | 5-Aug | 2.7 | 1.5-4.3                   |
| VA    | 81,229               | 344,965  | 151,448                     | 583,075 | 6-Aug | 4.2 | 1.9-7.2                   |
| VT    | 1,366                | 3,125    | 0                           | 11,500  | 5-Aug | 2.3 | 0.0-8.4                   |
| WA    | 50,006               | 153,181  | 59,084                      | 269,890 | 6-Aug | 3.1 | 1.2-5.4                   |
| WI    | 45,897               | 104,011  | 43,916                      | 183,753 | 6-Aug | 2.3 | 1.0-4.0                   |
| WV    | 5,548                | 21,949   | 4,207                       | 45,726  | 6-Aug | 4.0 | 0.8-8.2                   |
| WY    | 2,287                | .        | .                           | 5-Aug   | .     | .   | .                       |

\( ^{a}\)Cumulative cases reported on USAFacts\(^{11}\) as of 14 days before the median collection date of commercial laboratory residual sera specimens in each jurisdiction.

\( ^{b}\)Estimated infections are calculated by multiplying the overall seroprevalence estimate in each jurisdiction by the underlying population using 2018 American Community Survey 5-year population totals.\(^{1}\) Lower and upper estimated infections are calculated by multiplying the respective 95% confidence intervals for seroprevalence estimates by the underlying population.

\( ^{c}\)Median collection date of all samples in the corresponding jurisdiction during period 1.

\( ^{d}\)Unable to estimate overall seroprevalence in Hawaii, South Dakota, and Wyoming due to low sample sizes.

\( ^{e}\)Cumulative cases not reported on USAFacts.\(^{11}\)
eTable 2. Estimated number of infections based on period 4 seroprevalence estimates compared with the cumulative number of reported cases in each jurisdiction

| Jurisdiction | Reported Cases<sup>a</sup> | Estimated Infections<sup>b</sup> | Estimated Infections, Lower<sup>b</sup> | Estimated Infections, Upper<sup>b</sup> | Median Collection Date<sup>c</sup> | Ratio of Estimated Infections to Reported Cases | Ratio Range |
|--------------|----------------------------|----------------------------------|---------------------------------|---------------------------------|-------------------------------|---------------------------------|-------------|
| AK           | 5,363                      | 2,954                            | 812                             | 6,056                           | 16-Sep                        | 0.6                             | 0.2-1.1     |
| AL           | 122,183                    | 423,227                          | 301,124                         | 550,195                         | 11-Sep                        | 3.5                             | 2.5-4.5     |
| AR           | 59,579                     | 188,412                          | 137,571                         | 240,151                         | 11-Sep                        | 3.2                             | 2.3-4.0     |
| AZ           | 203,953                    | 375,121                          | 213,958                         | 591,858                         | 17-Sep                        | 1.8                             | 1.0-2.9     |
| CA           | 697,085                    | 1,918,289                        | 1,241,016                       | 2,681,690                       | 11-Sep                        | 2.8                             | 1.8-3.8     |
| CO           | 56,771                     | 182,528                          | 105,092                         | 272,132                         | 11-Sep                        | 3.2                             | 1.9-4.8     |
| CT           | 52,495                     | 111,027                          | 73,779                          | 156,512                         | 11-Sep                        | 2.1                             | 1.4-3.0     |
| DC           | 14,077                     | 44,492                           | 30,597                          | 56,745                          | 16-Sep                        | 3.2                             | 2.2-4.0     |
| DE           | 17,429                     | 71,212                           | 46,430                          | 99,697                          | 14-Sep                        | 4.1                             | 2.7-5.7     |
| FL           | 615,805                    | 1,750,842                        | 1,349,178                       | 2,199,881                       | 11-Sep                        | 2.8                             | 2.2-3.6     |
| GA           | 265,333                    | 1,338,673                        | 1,082,266                       | 1,625,973                       | 11-Sep                        | 5.0                             | 4.1-6.1     |
| HI           | 8,139                      | 11,376                           | 0                               | 31,000                          | 12-Sep                        | 1.4                             | 0.0-3.8     |
| IA           | 66,135                     | 238,070                          | 174,167                         | 313,876                         | 16-Sep                        | 3.6                             | 2.6-4.7     |
| ID           | 32,366                     | 87,766                           | 46,246                          | 142,789                         | 15-Sep                        | 2.7                             | 1.4-4.4     |
| IL           | 229,482                    | 576,967                          | 397,466                         | 778,265                         | 11-Sep                        | 2.5                             | 1.7-3.4     |
| IN           | 99,167                     | 265,497                          | 95,579                          | 583,430                         | 17-Sep                        | 2.7                             | 1.0-5.9     |
| KS           | 41,537                     | 101,807                          | 67,193                          | 140,785                         | 11-Sep                        | 2.5                             | 1.6-3.4     |
| KY           | 46,751                     | 159,847                          | 103,457                         | 231,335                         | 11-Sep                        | 3.4                             | 2.2-4.9     |
| LA           | 148,169                    | 582,952                          | 467,294                         | 727,990                         | 14-Sep                        | 3.9                             | 3.2-4.9     |
| MA           | 127,584                    | 252,717                          | 152,313                         | 352,438                         | 16-Sep                        | 2.0                             | 1.2-2.8     |
| MD           | 109,319                    | 612,350                          | 474,872                         | 761,236                         | 16-Sep                        | 5.6                             | 4.3-7.0     |
| ME           | 4,567                      | 6,664                            | 0                               | 11,595                          | 16-Sep                        | 1.5                             | 0.0-2.5     |
| MI           | 113,025                    | 368,427                          | 252,920                         | 490,904                         | 14-Sep                        | 3.3                             | 2.2-4.3     |
| MN           | 77,084                     | 442,189                          | 261,997                         | 631,777                         | 16-Sep                        | 5.7                             | 3.4-8.2     |
| MO           | 80,958                     | 213,152                          | 130,936                         | 305,112                         | 11-Sep                        | 2.6                             | 1.6-3.8     |
| MS           | 85,115                     | 236,112                          | 159,899                         | 324,878                         | 17-Sep                        | 2.8                             | 1.9-3.8     |
| MT           | 7,691                      | 22,918                           | 6,980                           | 45,628                          | 16-Sep                        | 3.0                             | 0.9-5.9     |
| NC           | 163,657                    | 690,582                          | 490,517                         | 900,804                         | 11-Sep                        | 4.2                             | 3.0-5.5     |
| ND           | 12,000                     | 9,026                            | 0                               | 25,575                          | 15-Sep                        | 0.8                             | 0.0-2.1     |
| NE           | 34,150                     | 127,619                          | 91,428                          | 169,143                         | 14-Sep                        | 3.7                             | 2.7-5.0     |
| NH           | 7,216                      | 9,405                            | 3,493                           | 17,736                          | 11-Sep                        | 1.3                             | 0.5-2.5     |
| NJ           | 192,972                    | 1,341,159                        | 1,123,553                       | 1,565,869                       | 17-Sep                        | 7.0                             | 5.8-8.1     |
| NM           | 25,041                     | 50,218                           | 24,900                          | 76,374                          | 11-Sep                        | 2.0                             | 1.0-3.0     |
| NV           | 67,841                     | 227,982                          | 172,448                         | 291,993                         | 11-Sep                        | 3.4                             | 2.5-4.3     |
| NY           | 438,040                    | 3,335,137                        | 2,887,836                       | 3,772,629                       | 18-Sep                        | 7.6                             | 6.6-8.6     |

© 2020 Bajema KL et al. JAMA Internal Medicine.
| State | OH  | OK   | OR   | PA   | PR   | RI   | SC   | SD   | TN   | TX   | UT   | VA   | VT   | WA   | WI   | WV   | WY   | 11/14 days before median collection date of commercial laboratory residual sera specimens in each jurisdiction. | Cumulative cases not reported on USAFacts. |
|-------|-----|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| OH    | 124,610 | 325,973 | 196,748 | 484,302 | 15-Sep | 2.6 | 1.6-3.9 |
| OK    | 56,258 | 195,907 | 134,784 | 256,246 | 11-Sep | 3.5 | 2.4-4.6 |
| OR    | 26,052 | 106,131 | 61,637 | 165,727 | 11-Sep | 4.1 | 2.4-6.4 |
| PA    | 136,771 | 1,419,821 | 1,132,020 | 1,753,671 | 17-Sep | 10.4 | 8.3-12.8 |
| PR    | 101,608 | 60,288 | 144,622 | 18-Sep | 1.3 | 0.6-2.4 |
| RI    | 21,197 | 28,528 | 12,151 | 51,880 | 11-Sep | 3.3 | 2.4-4.4 |
| SC    | 115,951 | 386,562 | 276,541 | 505,009 | 14-Sep | 1.2 | 0.0-3.1 |
| SD    | 13,506 | 15,557 | 41,659 | 11-Sep | 3.0 | 2.2-3.8 |
| TN    | 150,812 | 445,623 | 329,894 | 569,998 | 11-Sep | 3.8 | 2.8-4.8 |
| TX    | 609,750 | 2,286,586 | 1,717,728 | 2,919,580 | 11-Sep | 3.0 | 1.9-4.6 |
| UT    | 52,115 | 155,313 | 100,192 | 240,583 | 14-Sep | 2.2 | 1.3-3.5 |
| VA    | 121,606 | 269,241 | 152,289 | 431,627 | 15-Sep | 6.5 | 1.0-15.8 |
| VT    | 1,637 | 10,625 | 1,687 | 25,937 | 17-Sep | 2.5 | 1.3-3.8 |
| WA    | 73,294 | 182,358 | 94,097 | 279,373 | 11-Sep | 2.8 | 1.6-4.3 |
| WI    | 77,127 | 219,579 | 127,125 | 331,102 | 16-Sep | 2.2 | 0.9-3.7 |
| WV    | 10,640 | 23,778 | 9,328 | 39,873 | 16-Sep | 2.2 | 0.0-5.7 |
| WY    | 4,031 | 8,728 | 0 | 23,099 | 21-Sep | 2.2 | 0.0-5.7 |

aCumulative cases reported on USAFacts as of 14 days before the median collection date of commercial laboratory residual sera specimens in each jurisdiction.
bEstimated infections are calculated by multiplying the overall seroprevalence estimate in each jurisdiction by the underlying population using 2018 American Community Survey 5-year population totals. Lower and upper estimated infections are calculated by multiplying the respective 95% confidence intervals for seroprevalence estimates by the underlying population.
cMedian collection date of all samples in the corresponding jurisdiction during period 4.
dCumulative cases not reported on USAFacts.
eTable 3. Overall, sex-, age-, and metropolitan/nonmetropolitan-stratified SARS-CoV-2 prevalence estimates and 95% confidence intervals by jurisdiction during period 1

| Jurisdiction | Collection Dates | Number of Specimens | Overall | C.I. | Male | C.I. | Female | C.I. | Age <18 | C.I. | Age 18-49 | C.I. | Age 50-64 | C.I. | Age ≥65 | C.I. | Metro Counties | C.I. | Non-metro Counties | C.I. |
|--------------|------------------|---------------------|---------|------|------|------|--------|------|---------|------|-----------|------|-----------|------|---------|------|-----------------|------|------------------|------|
| AK           | 08/06 - 08/11/2020 | 242                 | 0.3     | 0.00-1.12* | 0.0 | 0.00-4.11** | 0.7 | 0.00-2.35* | †   | 0.7 | 0.00-2.23* | 0.0 | 0.00-4.35** | †   | 0.5 | 0.00-1.55* | † |
| AL           | 07/29 - 08/13/2020 | 938                 | 5.8     | 4.16-7.71 | 4.9 | 2.50-7.97 | 6.6 | 4.39-9.15 | 10.2 | 5.61-14.83 | 4.7 | 1.86-7.80 | 5.9 | 2.71-10.00 | 2.3 | 0.60-4.63 | 5.2 | 3.42-7.46 | 7.5 | 4.01-11.85 |
| AR           | 07/29 - 08/13/2020 | 937                 | 4.1     | 2.74-5.63 | 3.8 | 1.86-6.10 | 4.3 | 2.40-6.68 | 5.0 | 2.00-8.60 | 4.7 | 2.17-7.88 | 4.2 | 1.38-7.50 | 1.5 | 0.00-3.29 | 3.8 | 2.28-5.53 | 4.5 | 2.44-7.26 |
| AZ           | 07/31 - 08/11/2020 | 591                 | 8.2     | 4.11-13.59 | 9.0 | 2.20-17.70 | 7.5 | 3.26-13.56 | †   | 10.8 | 3.61-20.32 | 7.1 | 0.74-14.83* | 5.5 | 0.18-12.19* | 8.6 | 4.19-14.20 | †   |
| CA           | 07/30 - 08/05/2020 | 980                 | 5.7     | 4.05-7.77 | 5.1 | 2.74-7.83 | 6.3 | 3.97-9.19 | 6.2 | 3.12-10.09 | 7.0 | 3.90-10.30 | 5.2 | 2.46-8.82 | 1.1 | 0.00-2.61* | 5.7 | 4.05-7.82 | †   |
| CO           | 07/30 - 08/07/2020 | 1,001               | 2.4     | 0.89-4.53 | 2.7 | 0.75-5.72 | 2.1 | 0.49-4.94 | 4.3 | 0.63-10.52* | 1.1 | 0.00-2.75* | 4.3 | 0.34-11.31* | 0.8 | 0.00-2.07* | 1.6 | 0.71-2.62 | †   |
| CT           | 07/30 - 08/03/2020 | 994                 | 3.4     | 2.04-4.72 | 4.2 | 2.13-6.42 | 2.5 | 1.18-4.10 | 3.9 | 1.48-6.46 | 3.1 | 1.00-5.62 | 3.7 | 1.30-6.30 | 2.7 | 0.50-5.17 | 3.5 | 2.15-4.97 | †   |
| DC           | 07/30 - 08/13/2020 | 717                 | 3.9     | 2.18-5.76 | 3.3 | 1.27-5.93 | 4.4 | 2.06-7.53 | †   | 1.4 | 0.00-3.09* | 5.5 | 2.28-9.15 | 6.4 | 3.28-9.94 | 3.9 | 2.18-5.76 | NA  |
| DE           | 07/29 - 08/13/2020 | 804                 | 5.7     | 3.55-8.22 | 4.3 | 2.13-7.12 | 7.0 | 4.02-10.92 | †   | 8.3 | 4.31-12.72 | 5.0 | 2.24-8.34 | 0.9 | 0.00-2.29* | 5.7 | 3.55-8.22 | NA  |
| FL           | 07/31 - 08/03/2020 | 980                 | 4.3     | 2.77-5.86 | 5.2 | 2.67-7.95 | 3.5 | 1.78-5.34 | 3.8 | 1.57-6.35 | 5.4 | 2.28-8.78 | 3.7 | 1.22-6.46 | 3.3 | 0.96-6.22 | 4.1 | 2.74-5.66 | †   |
| GA           | 08/02 - 08/11/2020 | 985                 | 6.8     | 4.83-8.81 | 8.1 | 5.08-11.86 | 5.6 | 3.35-8.43 | 8.6 | 4.78-12.54 | 7.8 | 4.18-11.09 | 4.9 | 2.02-7.86 | 2.8 | 0.80-5.52 | 6.5 | 4.52-8.33 | 8.6 | 3.19-14.70 |
| HI           | 08/03 - 08/11/2020 | 5                   | †       | †       | †       | †   | †       | †   | †       | †   | †       | †   | †       | †   | †       | †   | †       | †   |
| IA           | 07/29 - 08/13/2020 | 811                 | 8.6     | 5.98-11.34 | 4.6 | 1.85-7.40 | 12.5 | 8.54-17.01 | †   | 11.4 | 7.12-16.11 | 6.5 | 2.92-9.93 | 2.5 | 0.44-5.12 | 11.7 | 7.76-15.82 | 4.1 | 1.98-6.34 |
| ID           | 08/04 - 08/11/2020 | 246                 | 4.5     | 1.80-7.99 | 7.0 | 2.04-14.12 | 2.1 | 0.16-5.31* | †   | 10.3 | 3.75-19.04 | †   | 1.3 | 0.00-4.51* | 6.7 | 2.69-11.94 | †   |
| IL           | 07/29 - 08/10/2020 | 1,004               | 3.9     | 2.52-5.21 | 3.5 | 1.62-5.64 | 4.3 | 2.59-6.32 | 5.1 | 1.96-8.55 | 3.8 | 1.60-6.24 | 3.5 | 1.43-5.78 | 3.1 | 1.18-5.51 | 4.4 | 2.85-5.89 | †   |

© 2020 Bajema KL et al. JAMA Internal Medicine.
| Jurisdiction | Collection Dates | Number of Specimens | Overall  | Male  | Female  | Age <18 | Age 18-49 | Age 50-64 | Age ≥65 | Metro Counties | Non-metro Counties |
|--------------|------------------|---------------------|---------|-------|---------|---------|----------|----------|--------|---------------|-------------------|
| IN           | 07/31 - 08/11/2020 | 579                | 2.2     | 1.10-3.63 | 1.4     | 0.00-3.30* | 3.0     | 1.16-5.46 | 3.3     | 0.97-6.16    | 4.4     | 1.08-9.53    | 0.0     | 0.00-2.56** | 2.1     | 1.02-3.69†   |
| KS           | 07/29 - 08/08/2020 | 962                | 1.6     | 0.70-2.80 | 1.4     | 0.28-2.84 | 1.8     | 0.44-3.46 | 1.6     | 0.00-3.74    | 1.9     | 0.33-4.26    | 1.5     | 0.00-3.36   | 0.9     | 0.00-2.51*   |
| KY           | 07/30 - 08/13/2020 | 975                | 2.4     | 1.32-3.62 | 2.2     | 0.65-4.06 | 2.7     | 1.16-4.39 | 4.1     | 1.66-7.21    | 2.1     | 0.34-4.34    | 2.2     | 0.42-4.31   | 1.3     | 0.00-3.17*   |
| LA           | 07/28 - 08/13/2020 | 1,002              | 9.6     | 6.88-12.29 | 8.9     | 5.10-13.35 | 10.2    | 6.91-13.74 | 11.7    | 6.99-17.33   | 10.6    | 6.64-15.17   | 9.9     | 4.06-18.63  | 2.7     | 0.73-5.06   |
| MA           | 07/30 - 08/10/2020 | 978                | 4.2     | 2.89-5.81 | 4.8     | 2.83-7.36 | 3.7     | 1.94-5.43 | 6.2     | 3.13-9.64    | 3.4     | 1.19-6.05    | 4.6     | 1.81-7.29   | 3.5     | 1.29-6.01   |
| MD           | 07/31 - 08/11/2020 | 783                | 9.7     | 7.26-12.87 | 11.5    | 6.57-16.74 | 8.1     | 5.18-11.83 | 11.6    | 7.13-15.96   | 5.7     | 3.04-8.61    | 2.8     | 0.93-5.07   | 9.7     | 7.26-12.87†† |
| ME           | 07/30 - 08/11/2020 | 598                | 0.5     | 0.00-1.16 | 1.0     | 0.00-2.37 | 0.0     | 0.00-1.01** | 0.4     | 0.00-1.46*   | 1.2     | 0.00-3.28*   | 0.4     | 0.00-1.56*   | 0.8     | 0.00-1.96   |
| MI           | 07/30 - 08/11/2020 | 982                | 3.4     | 2.16-4.84 | 3.9     | 2.00-6.07 | 2.8     | 1.31-4.67 | 6.7     | 3.64-10.40   | 3.6     | 1.39-6.48    | 1.8     | 0.00-3.83   | 0.3     | 0.00-1.28*  |
| MN           | 07/29 - 08/13/2020 | 879                | 3.5     | 2.06-5.01 | 3.2     | 1.08-5.61 | 3.8     | 1.95-5.68 | 3.7     | 1.03-7.02    | 4.5     | 2.16-7.08    | 1.6     | 0.32-3.10   | 3.2     | 0.00-9.08*  |
| MO           | 07/28 - 08/10/2020 | 979                | 2.5     | 1.44-3.61 | 1.7     | 0.55-3.19 | 3.3     | 1.45-5.19 | 3.2     | 1.12-5.45    | 2.9     | 0.96-5.15    | 2.1     | 0.33-4.46   | 1.1     | 0.00-3.25*  |
| MS           | 07/30 - 08/13/2020 | 769                | 7.1     | 3.75-11.09 | 4.0     | 1.23-7.81 | 10.0    | 4.05-17.18 | 6.2     | 2.83-10.12   | 5.0     | 2.09-8.73    | 2.6     | 0.54-5.49*  | 5.8     | 2.99-9.17   |
| MT           | 07/29 - 08/10/2020 | 199                | 0.5     | 0.00-1.67* | 0.0     | 0.00-4.20** | 0.9     | 0.00-3.37* | ††      | ††           | ††      | ††           | ††      | 1.3     | 0.00-4.75*   |
| NC           | 07/29 - 08/10/2020 | 928                | 2.5     | 1.31-3.72 | 1.6     | 0.31-3.10 | 3.3     | 1.66-5.20 | 6.4     | 2.84-10.49   | 1.6     | 0.35-3.50*   | 0.9     | 0.00-2.33*   | 1.0     | 0.00-2.52*   | 2.2     | 1.06-3.47   |
| ND           | 07/29 - 08/12/2020 | 121                | 7.3     | 1.30-14.28 | ††      | ††           | ††      | ††           | ††      | ††           | ††      | 0.5     | 0.00-2.16*   |
| NE           | 07/28 - 08/13/2020 | 954                | 7.4     | 5.25-9.75 | 8.2     | 4.62-12.06 | 6.6     | 4.12-9.34 | 10.2    | 4.83-16.49   | 8.1     | 4.41-12.18   | 7.6     | 3.40-12.51  | 0.8     | 0.00-2.91*  |
| NH           | 07/30 - 08/11/2020 | 809                | 0.8     | 0.22-1.48 | 1.0     | 0.14-2.08 | 0.6     | 0.00-1.39* | ††      | ††           | ††      | 1.0     | 0.00-2.42*   | 0.3     | 0.00-1.31*   | 1.7     | 0.25-3.72   |
| NJ           | 07/31 - 08/11/2020 | 871                | 14.8    | 12.23-17.57 | 15.3    | 11.04-20.10 | 14.3    | 10.82-17.84 | 22.3    | 16.60-28.90 | 14.2    | 9.29-19.31   | 12.0    | 7.58-16.93  | 9.5     | 5.05-13.96  |

© 2020 Bajema KL et al. JAMA Internal Medicine.
| Jurisdiction | Collection Dates | Number of Specimens | Overall | Male | Female | Age <18 | Age 18-49 | Age 50-64 | Age ≥65 | Metro Counties | Non-metro Counties |
|--------------|------------------|---------------------|---------|------|--------|---------|----------|----------|--------|----------------|-------------------|
| NM           | 07/29 - 08/13/2020 | 964                | 2.0     | 0.6  | 0.00-1.84* | 3.3 | 1.84-5.11 | 3.1 | 0.70-6.30* | 1.8 | 0.63-3.69 | 2.6 | 0.68-4.86 | 0.3 | 0.00-0.99* | 2.4 | 1.26-3.67 | 1.2 | 0.00-2.77** |
| NV           | 07/30 - 08/02/2020 | 979                | 5.1     | 5.3  | 2.87-8.07 | 4.9 | 3.19-6.86 | 8.9 | 5.36-12.85 | 4.2 | 1.69-7.30 | 4.0 | 1.78-6.61 | 3.1 | 1.14-5.64 | 5.7 | 4.00-7.35   |
| NY           | 07/31 - 08/11/2020 | 846                | 23.3    | 21.6 | 16.81-27.10 | 24.9 | 20.81-29.17 | 26.7 | 20.64-33.36 | 29.7 | 22.63-36.55 | 17.8 | 12.68-23.16 | 7.9 | 4.18-11.64 | 25.1 | 21.59-28.32 | 0.0 | 3.00-3.62** |
| OH           | 07/29 - 08/11/2020 | 786                | 2.3     | 2.5  | 0.70-4.69 | 2.1 | 0.65-3.76 | 3.3 | 0.00-8.03* | 1.3 | 0.15-2.71 | 3.6 | 0.78-6.97 | 1.5 | 0.28-3.07 | 2.9 | 1.39-4.52 | 0.0 | 0.00-2.84** |
| OK           | 07/28 - 08/04/2020 | 979                | 1.6     | 1.4  | 0.29-2.74 | 1.8 | 0.78-3.03 | 3.6 | 1.28-6.20 | 0.4 | 0.00-1.32* | 1.8 | 0.00-4.14* | 1.5 | 0.00-3.50* | 1.6 | 0.82-2.62 | 1.5 | 0.25-2.98 |
| OR           | 08/05 - 08/11/2020 | 658                | 2.3     | 2.3  | 0.36-5.19* | 2.3 | 0.73-4.00 | 5.6 | 0.87-12.05* | 2.2 | 0.54-4.03 †† | 0.6 | 0.00-1.67* | 2.8 | 1.18-4.50   |
| PA           | 07/31 - 08/11/2020 | 575                | 10.2    | 9.5  | 6.33-13.61 | 11.0 | 3.26-22.51 † | 12.8 | 8.91-17.84 | 8.5 | 3.76-14.00 | 1.2 | 0.00-3.34* | 11.5 | 6.45-19.44 | 0.5 | 0.00-1.93* |
| PR           | 07/27 - 08/07/2020 | 984                | 1.1     | 1.4  | 0.39-2.56 | 0.8 | 0.12-1.69* | 0.0 | 0.00-1.49** | 0.4 | 0.00-1.35* | 2.5 | 0.53-5.15* | 2.2 | 0.52-4.99* | 1.1 | 0.45-1.90   |
| RI           | 07/30 - 08/11/2020 | 684                | 3.0     | 2.7  | 0.99-4.64 | 3.4 | 0.65-7.70 † | 2.3 | 0.45-4.65 | 4.1 | 1.14-7.37 | 1.7 | 0.00-3.69 | 3.0 | 1.23-5.51   |
| SC           | 07/30 - 08/13/2020 | 840                | 8.1     | 9.4  | 5.62-13.51 | 6.9 | 4.08-9.88 | 11.6 | 4.48-20.14 | 9.2 | 5.45-13.32 | 6.9 | 3.74-10.92 | 2.1 | 0.52-4.25* | 8.2 | 5.78-11.07 | 7.2 | 2.85-11.76 |
| SD           | 07/29 - 08/12/2020 | 47                 | ††       | ††   | ††      | ††   | ††      | ††   | ††      | ††   | ††      | ††   | ††      | ††   | ††      | ††   | ††      |
| TN           | 07/30 - 08/11/2020 | 1,003              | 6.3     | 6.4  | 3.43-9.84 | 6.2 | 4.22-8.66 | 8.3 | 4.93-12.27 | 8.4 | 4.69-12.40 | 2.5 | 0.69-5.21 | 2.6 | 0.66-5.01 | 7.4 | 5.20-9.64 | 2.7 | 0.32-6.40* |
| TX           | 07/29 - 08/05/2020 | 986                | 5.9     | 6.2  | 3.61-8.88 | 5.5 | 2.95-8.31 | 8.4 | 4.78-13.05 | 5.6 | 2.94-9.06 | 5.5 | 2.32-9.42 | 1.9 | 0.34-4.02* | 5.9 | 4.07-8.15 | 5.3 | 1.02-11.70* |
| UT           | 07/30 - 08/11/2020 | 880                | 3.2     | 2.2  | 0.62-3.92 | 4.2 | 1.77-7.50 † | 4.3 | 1.96-6.73 | 3.1 | 1.13-5.53 | 1.3 | 0.00-3.26* | 3.3 | 1.71-5.18 | 1.9 | 0.00-6.76* |
| VA           | 07/31 - 08/11/2020 | 730                | 4.1     | 2.7  | 0.57-5.24 | 5.5 | 1.54-10.71 † | 3.9 | 1.46-6.77 | 2.4 | 0.26-5.12 | 2.2 | 0.39-4.72 | 4.6 | 2.03-7.86 | 0.6 | 0.00-2.08* |
| VT           | 07/30 - 08/11/2020 | 346                | 0.5     | 1.0  | 0.00-3.74* | 0.0 | 0.00-1.67** | 1.1 | 0.00-4.42* | 0.0 | 0.00-3.77** | 0.0 | 0.00-3.89** | 1.3 | 0.00-5.28* | 0.0 | 0.00-1.46** |
| WA           | 07/29 - 08/11/2020 | 684                | 2.1     | 2.0  | 0.25-4.27* | 2.3 | 0.72-4.20 | 0.5 | 0.00-1.84* | 3.9 | 1.27-7.07 | 1.0 | 0.00-2.34* †† | 2.3 | 0.90-3.97   |   |          |

© 2020 Bajema KL et al. *JAMA Internal Medicine.*
| Jurisdiction | Collection Dates | Number of Specimens | Overall | Male | Female | Age <18 | Age 18-49 | Age 50-64 | Age ≥65 | Metro Counties | Non-metro Counties |
|--------------|------------------|---------------------|---------|------|--------|---------|-----------|-----------|---------|----------------|------------------|
| WI           | 07/30 - 08/13/2020 | 814 | 1.8 | 0.76-3.18 | 2.0 | 0.26-3.96 | 1.7 | 0.41-3.40 | 2.4 | 0.00-6.28* | 2.2 | 0.45-4.31 | 1.4 | 0.00-3.65* | 0.8 | 0.00-2.18* | 2.1 | 0.76-3.69 | 1.2 | 0.00-3.29* |
| WV           | 07/30 - 08/13/2020 | 317 | 1.2 | 0.23-2.50 | 1.5 | 0.00-3.48* | 0.9 | 0.00-2.55* | † |             | 1.7 | 0.00-4.74* | 0.4 | 0.00-1.85* | † |             | 1.9 | 0.37-3.86 | † |          |
| WY           | 07/29 - 08/11/2020 | 71  | † | † | † | † | † | † | † | † | † | † | † | † | † | † |          |

†† No specimens were collected for the subgroup in period 1. Estimates are not shown.
† Because of small cell size (n < 75) for the subgroup in period 1, estimates are not shown.
* The confidence interval surrounding the estimate is large (i.e., high variance) relative to the estimate itself (RHWCI > 1.0). Associated point estimates should be interpreted with caution.
** No positive specimens were reported for the subgroup in period 1; confidence intervals were computed separately using Clopper-Pearson Exact method.
*** No specimen records received and analyzed for the jurisdiction in period 1.
NA indicates jurisdictions that do not have non-metro counties.
eTable 4. Overall, sex-, age-, and metropolitan/nonmetropolitan-stratified SARS-CoV-2 prevalence estimates and 95% confidence intervals by jurisdiction during period 2

| Jurisdiction | Collection Dates       | Number of Specimens | Overall % | C.I. | Male % | C.I. | Female % | C.I. | Age <18 % | C.I. | Age 18-49 % | C.I. | Age 50-64 % | C.I. | Age ≥65 % | C.I. | Metro Counties % | C.I. | Non-metro Counties % | C.I. |
|--------------|------------------------|---------------------|-----------|------|--------|------|----------|------|-----------|------|-------------|------|-------------|------|------------|------|-------------------|------|---------------------|------|
| AK           | 08/12 - 08/26/2020     | 704                 | 1.3       | 0.50-2.33 | 0.9 | 0.00-2.20 | 1.7 | 0.53-3.20 | 2.5 | 0.81-4.85 | 0.8 | 0.00-2.65 | 0.0 | 0.00-2.32 | 1.4 | 0.56-2.53 | 0.9 | 0.00-2.70 |
| AL           | 08/12 - 08/26/2020     | 974                 | 7.6       | 5.33-9.76 | 8.8 | 5.22-12.38 | 6.5 | 4.06-9.28 | 11.0 | 6.16-16.57 | 9.9 | 6.01-14.37 | 3.6 | 1.46-6.12 | 2.0 | 0.35-4.16 | 7.3 | 4.88-9.67 | 8.5 | 4.47-13.30 |
| AR           | 08/11 - 08/25/2020     | 998                 | 3.0       | 1.76-4.35 | 3.3 | 1.26-5.70 | 2.8 | 1.33-4.36 | 3.9 | 0.84-7.45 | 3.2 | 1.08-5.60 | 3.9 | 1.44-7.18 | 0.5 | 0.00-1.50 | 3.8 | 2.06-5.48 | 1.7 | 0.49-3.20 |
| AZ           | 08/12 - 08/26/2020     | 1,304               | 4.7       | 2.70-7.61 | 5.5 | 1.82-10.69 | 3.9 | 1.82-7.01 | †   | 7.4 | 3.94-12.04 | 5.6 | 0.66-12.71 | 0.0 | 0.00-3.36 | 5.0 | 2.85-8.01 | †   |          |
| CA           | 08/13 - 08/19/2020     | 980                 | 4.3       | 2.85-6.06 | 4.8 | 2.62-7.31 | 3.9 | 1.83-6.05 | 5.6 | 2.55-8.94 | 4.8 | 2.22-7.97 | 2.3 | 0.67-4.59 | 3.5 | 1.21-6.77 | 4.3 | 2.85-6.06 | † † |          |
| CO           | 08/10 - 08/25/2020     | 1,019               | 3.3       | 1.83-4.80 | 3.4 | 1.34-5.69 | 3.2 | 1.61-5.11 | 3.3 | 1.18-5.69 | 4.8 | 2.05-7.81 | 1.7 | 0.34-3.33 | 0.5 | 0.00-1.65 | 3.8 | 2.09-5.49 | †   |          |
| CT           | 08/11 - 08/24/2020     | 983                 | 2.4       | 1.45-3.52 | 2.2 | 0.85-3.87 | 2.6 | 1.38-4.26 | 5.1 | 1.95-8.16 | 1.0 | 0.00-2.70 | 2.8 | 0.71-5.11 | 2.0 | 0.32-3.97 | 2.5 | 1.48-3.63 | †   |          |
| DC           | 08/13 - 08/27/2020     | 781                 | 6.8       | 4.59-9.21 | 5.5 | 2.48-9.17 | 8.0 | 4.85-11.64 | †   | 8.3 | 4.77-12.02 | 5.5 | 2.52-8.91 | 2.9 | 1.05-5.23 | 6.8 | 4.59-9.21 | NA  |          |
| DE           | 08/12 - 08/27/2020     | 1,004               | 8.5       | 5.79-11.25 | 9.7 | 5.32-14.62 | 7.3 | 4.14-10.62 | †   | 9.3 | 5.26-13.82 | 6.3 | 3.29-9.23 | 2.1 | 0.68-3.72 | 8.5 | 5.79-11.25 | NA  |          |
| FL           | 08/14 - 08/14/2020     | 978                 | 4.5       | 3.15-6.06 | 4.6 | 2.41-7.31 | 4.3 | 2.42-6.34 | 6.4 | 3.13-9.94 | 5.4 | 2.47-8.88 | 2.7 | 0.75-5.38 | 2.3 | 0.44-4.78 | 4.6 | 3.22-6.23 | †   |          |
| GA           | 08/13 - 08/26/2020     | 1,031               | 7.4       | 5.52-9.51 | 8.3 | 5.35-11.68 | 6.5 | 4.23-9.32 | 9.6 | 5.64-13.96 | 6.4 | 3.38-9.84 | 7.2 | 3.45-11.88 | 6.8 | 2.80-12.09 | 8.1 | 6.03-10.22 | †   |          |
| HI           | 08/14 - 08/26/2020     | 9                   | †         | †         | †   | †         | †   | †         | †   | †         | †   | †         | †   | †         | †   | †         | †   |          |
| IA           | 08/12 - 08/27/2020     | 980                 | 9.4       | 7.12-11.63 | 7.8 | 5.02-11.66 | 10.9 | 7.54-14.88 | †   | 11.9 | 7.93-15.81 | 9.1 | 6.01-12.49 | 4.5 | 1.92-7.39 | 12.0 | 8.19-15.40 | 5.7 | 3.55-8.13 |
| ID           | 08/12 - 08/26/2020     | 651                 | 4.6       | 1.67-9.05 | 4.8 | 0.69-12.76 | 4.3 | 1.42-8.73 | †   | 2.6 | 0.54-4.99 | 5.1 | 1.44-9.73 | 3.1 | 1.05-5.78 | 5.7 | 1.80-11.65 | 2.3 | 0.00-6.70 | †   |          |
| IL           | 08/12 - 08/27/2020     | 985                 | 4.9       | 3.40-6.65 | 5.1 | 3.01-7.38 | 4.8 | 2.44-7.08 | 3.5 | 1.17-6.40 | 7.4 | 4.23-10.90 | 3.4 | 1.30-6.12 | 2.0 | 0.58-3.71 | 5.6 | 3.84-7.52 | †   |          |
| Jurisdiction | Collection Dates | Number of Specimens | Overall | Male | Female | Age <18 | Age 18-49 | Age 50-64 | Age ≥65 | Metro Counties | Non-metro Counties |
|--------------|------------------|---------------------|---------|------|--------|--------|----------|----------|--------|---------------|------------------|
| IN           | 08/12 - 08/26/2020 | 906                | 3.1 | 1.53-4.76 | 2.9 | 0.45-6.11 | 3.2 | 1.69-5.18 | 5.0 | 2.63-7.71 | 0.9 | 0.00-3.07* | 5.4 | 0.00-14.17* | 2.4 | 1.23-3.76 | 5.4 | 0.00-12.20* |
| KS           | 08/11 - 08/25/2020 | 1,016              | 3.7 | 2.02-5.47 | 4.4 | 1.71-7.11 | 3.0 | 1.08-5.04 | 2.1 | 0.28-4.30 | 6.0 | 2.51-9.99 | 3.4 | 0.74-6.92 | 0.4 | 0.00-1.41* | 1.4 | 0.48-2.45 | 8.5 | 4.05-13.53 |
| KY           | 08/12 - 08/26/2020 | 1,126              | 3.1 | 2.05-4.49 | 4.1 | 2.26-6.08 | 2.1 | 0.89-3.81 | 4.2 | 1.70-6.94 | 3.5 | 1.47-6.03 | 2.8 | 1.07-4.85 | 1.0 | 0.00-2.58* | 4.5 | 2.84-6.56 | 1.2 | 0.20-2.54 |
| LA           | 08/12 - 08/25/2020 | 989                | 11.8 | 9.27-14.81 | 10.4 | 7.00-14.49 | 13.2 | 9.31-17.57 | 12.2 | 7.68-17.67 | 11.0 | 6.84-16.36 | 16.7 | 10.74-23.60 | 6.8 | 3.46-11.33 | 12.3 | 9.96-15.14 | 1 | |
| MA           | 08/12 - 08/27/2020 | 980                | 3.7 | 2.27-5.21 | 4.4 | 2.22-6.78 | 3.0 | 1.49-4.97 | 4.2 | 1.69-7.37 | 4.6 | 2.14-7.84 | 2.4 | 0.48-4.70 | 2.1 | 0.34-4.47 | 3.7 | 2.27-5.21 | 1 |  |
| MD           | 08/10 - 08/26/2020 | 1,174              | 7.0 | 4.92-9.33 | 7.9 | 4.22-11.37 | 6.2 | 3.78-8.98 | 7.9 | 5.30-11.00 | 4.6 | 2.33-7.26 | 3.8 | 1.88-6.10 | 7.1 | 5.03-9.45 | 1 |  |
| ME           | 08/12 - 08/27/2020 | 609                | 0.6 | 0.00-1.44* | 0.0 | 0.00-1.53** | 1.2 | 0.00-2.82* | 1.4 | 0.00-3.63* | 0.0 | 0.00-2.10** | 0.2 | 0.00-1.02* | 0.6 | 0.00-1.34 | 0.6 | 0.00-2.25* |
| MI           | 08/12 - 08/25/2020 | 983                | 4.2 | 2.88-5.76 | 4.8 | 2.62-7.37 | 3.5 | 1.80-5.52 | 6.0 | 3.09-9.18 | 3.9 | 1.39-6.81 | 3.9 | 1.47-7.17 | 2.7 | 0.79-4.86 | 4.6 | 3.10-6.37 | 2.3 | 0.00-5.94* |
| MN           | 08/11 - 08/27/2020 | 978                | 4.5 | 3.05-5.87 | 4.3 | 2.49-6.41 | 4.6 | 2.85-6.68 | 2.3 | 0.38-4.80 | 5.6 | 3.00-8.50 | 5.3 | 2.65-7.98 | 3.6 | 1.50-6.03 | 5.8 | 3.92-7.56 | 1 |  |
| MO           | 08/12 - 08/21/2020 | 1,021              | 3.5 | 2.23-5.06 | 2.8 | 1.11-5.15 | 4.1 | 2.24-6.23 | 3.7 | 1.30-6.63 | 4.3 | 1.85-7.45 | 3.1 | 1.26-5.34 | 1.6 | 0.00-3.77* | 3.4 | 2.15-4.95 | 3.6 | 0.62-7.88 |
| MS           | 08/12 - 08/27/2020 | 968                | 10.0 | 6.69-14.71 | 8.1 | 4.60-12.80 | 11.8 | 6.69-19.81 | 13.0 | 8.64-17.97 | 9.1 | 5.65-13.25 | 3.1 | 1.16-5.95 | 9.5 | 6.14-14.94 | 10.4 | 5.47-17.92 |
| MT           | 08/12 - 08/24/2020 | 383                | 1.3 | 0.38-2.49 | 0.7 | 0.00-2.51* | 1.9 | 0.40-3.93 | 1.7 | 0.00-4.55* | 0.0 | 0.00-2.78** | 3.6 | 0.66-7.20 | 1.3 | 0.00-3.97* | 1.3 | 0.21-2.88 |
| NC           | 08/11 - 08/27/2020 | 982                | 3.8 | 2.33-5.29 | 3.2 | 1.24-5.68 | 4.3 | 2.33-6.43 | 4.1 | 1.72-6.93 | 3.4 | 1.27-6.11 | 6.1 | 3.20-9.98 | 1.3 | 0.25-3.12* | 3.1 | 1.82-4.71 | 6.1 | 2.86-9.74 |
| ND           | 08/12 - 08/26/2020 | 135                | 0.6 | 0.00-1.45* | † | 1.3 | 0.00-2.99* | † | † | † | † | 1.2 | 0.00-2.92* | † | |
| NE           | 08/11 - 08/25/2020 | 990                | 7.9 | 5.51-10.61 | 8.6 | 4.80-13.19 | 7.2 | 4.46-10.44 | 10.0 | 6.45-13.73 | 4.5 | 2.44-6.93 | 2.9 | 0.93-5.54 | 8.8 | 6.24-11.77 | 6.2 | 1.44-12.43 |
| NH           | 08/13 - 08/25/2020 | 1,125              | 0.8 | 0.30-1.22 | 0.9 | 0.23-1.70 | 0.6 | 0.10-1.30 | † | 0.8 | 0.00-1.64 | 1.3 | 0.23-2.42 | 1.0 | 0.00-2.29 | 1.2 | 0.48-1.94 | 0.0 | 0.00-1.79** |
| NJ           | 08/10 - 08/26/2020 | 1,127              | 12.2 | 10.15-14.53 | 11.0 | 7.88-14.46 | 13.4 | 10.59-16.23 | 16.9 | 11.31-21.99 | 14.2 | 10.30-18.50 | 7.3 | 4.33-10.26 | 6.7 | 3.93-10.08 | 12.2 | 10.15-14.53 | NA | |

© 2020 Bajema KL et al. JAMA Internal Medicine.
| Jurisdiction | Collection Dates | Number of Specimens | Overall % | C.I. | Male % | C.I. | Female % | C.I. | Age <18 % | C.I. | Age 18-49 % | C.I. | Age 50-64 % | C.I. | Age ≥65 % | C.I. | Metro Counties % | C.I. | Non-metro Counties % | C.I. |
|--------------|------------------|---------------------|-----------|------|--------|------|----------|------|-----------|------|--------------|------|--------------|------|--------------|------|------------------|------|----------------------|------|
| NM | 08/10 - 08/27/2020 | 976 | 2.5 | 1.47-3.79 | 2.2 | 0.50-4.15 | 2.8 | 1.39-4.47 | 4.1 | 0.98-8.07 | 2.2 | 0.55-4.28 | 2.7 | 0.94-5.16 | 0.8 | 0.00-2.00† | 2.7 | 1.35-4.07 | 2.1 | 0.28-4.49† |
| NV | 08/12 - 08/26/2020 | 972 | 7.9 | 6.13-9.83 | 8.9 | 5.93-12.39 | 7.0 | 4.83-9.36 | 9.7 | 5.94-13.45 | 7.8 | 4.68-11.11 | 8.0 | 4.71-11.44 | 5.4 | 2.80-8.70 | 8.7 | 6.76-10.84† |
| NY | 08/10 - 08/26/2020 | 1,122 | 20.6 | 18.04-23.14 | 20.6 | 16.69-24.78 | 20.5 | 17.21-24.14 | 25.2 | 19.71-30.91 | 22.2 | 17.52-27.19 | 16.8 | 12.74-21.44 | 14.6 | 10.95-18.43 | 22.1 | 19.40-24.89† |
| OH | 08/12 - 08/27/2020 | 985 | 2.1 | 1.06-3.29 | 1.7 | 0.37-3.50 | 2.4 | 1.04-4.22 | 2.5 | 0.00-6.35† | 2.0 | 0.43-4.09 | 2.6 | 0.89-4.67 | 1.0 | 0.00-2.58† | 2.3 | 1.13-3.82 | 1.0 | 0.00-2.31† |
| OK | 08/10 - 08/18/2020 | 979 | 4.0 | 2.72-5.51 | 3.5 | 1.50-5.76 | 4.6 | 2.85-6.79 | 6.9 | 3.69-10.78 | 3.4 | 1.34-6.08 | 1.7 | 0.29-3.73† | 3.8 | 1.23-6.57 | 4.0 | 2.55-5.80 | 4.0 | 1.96-6.56 |
| OR | 08/10 - 08/27/2020 | 1,086 | 2.4 | 1.41-3.60 | 1.5 | 0.42-2.85 | 3.2 | 1.53-5.18 | 2.0 | 0.00-5.11† | 2.9 | 1.35-4.99 | 1.7 | 0.40-3.31 | 2.1 | 0.42-4.40 | 2.5 | 1.43-3.80 | 1.6 | 0.00-4.73† |
| PA | 08/10 - 08/26/2020 | 887 | 10.1 | 7.53-13.74 | 15.5 | 10.51-22.76 | 4.8 | 2.84-7.24† | 15.7 | 12.87-18.78 | 9.5 | 4.73-14.73 | 2.1 | 0.00-4.87† | 11.1 | 8.32-15.40 | 2.0 | 0.37-4.52† |
| PR | 08/10 - 08/17/2020 | 986 | 2.2 | 1.18-3.26 | 1.6 | 0.38-3.31 | 2.6 | 1.11-4.54 | 1.0 | 0.00-2.45† | 0.9 | 0.00-2.49† | 3.2 | 1.06-5.93 | 5.0 | 1.25-10.63† | 1.9 | 1.02-2.79† |
| RI | 08/12 - 08/27/2020 | 570 | 3.6 | 1.69-5.89 | 3.5 | 0.82-6.73 | 3.8 | 0.84-7.53† | 1.7 | 0.00-3.72 | 3.3 | 0.78-6.51 | 2.5 | 0.00-5.72† | 3.6 | 1.69-5.89 NA |
| SC | 08/12 - 08/27/2020 | 1,063 | 6.0 | 4.37-7.95 | 7.3 | 4.49-10.30 | 4.8 | 3.03-7.01 | 5.3 | 2.13-8.95 | 7.0 | 4.01-10.42 | 6.0 | 3.21-9.42 | 4.6 | 1.93-8.10 | 6.2 | 4.36-8.15 | 5.3 | 2.03-9.01 |
| SD | 08/12 - 08/26/2020 | 83 | 0.0 | 0.00-4.35** | † | † | † | † | † | † | † | † | † | † | † | † | † | † | † | † |
| TN | 08/12 - 08/26/2020 | 1,029 | 6.7 | 5.11-8.57 | 7.3 | 4.64-10.26 | 6.1 | 3.79-8.67 | 6.8 | 3.77-10.13 | 9.1 | 5.76-13.41 | 5.1 | 2.39-8.67 | 2.1 | 0.45-4.29† | 7.7 | 5.63-9.85 | 3.4 | 1.19-6.61 |
| TX | 08/12 - 08/24/2020 | 1,001 | 6.5 | 4.69-8.47 | 6.1 | 3.36-9.23 | 6.9 | 4.52-9.76 | 8.7 | 5.17-12.89 | 6.4 | 3.31-10.14 | 5.3 | 2.39-9.23 | 3.7 | 1.47-6.51 | 6.5 | 4.54-8.39† |
| UT | 08/15 - 08/25/2020 | 871 | 5.5 | 2.94-8.71 | 7.0 | 2.57-12.61 | 3.9 | 2.06-6.09† | 6.2 | 3.37-9.22 | 3.3 | 1.07-5.51 | 1.4 | 0.00-3.12 | 6.0 | 3.16-9.56 | 1.6 | 0.00-5.60† |
| VA | 08/10 - 08/26/2020 | 1,243 | 4.7 | 2.51-7.22 | 1.1 | 0.21-2.31 | 8.1 | 3.99-12.57† | 3.3 | 1.96-5.06 | 2.9 | 0.83-5.32 | 1.1 | 0.16-2.37 | 5.2 | 2.84-8.13 | 0.8 | 0.00-2.02† |
| VT | 08/12 - 08/27/2020 | 382 | 0.3 | 0.00-0.81* | 0.0 | 0.00-2.51** | 0.5 | 0.00-1.60* | † | 0.0 | 0.00-2.24** | 0.8 | 0.00-3.03* | 0.5 | 0.00-1.79* | 0.0 | 0.00-3.24** | 0.4 | 0.00-1.25* |
| WA | 08/12 - 08/27/2020 | 1,238 | 3.0 | 1.79-4.47 | 3.7 | 1.55-6.46 | 2.4 | 1.06-3.95 | 4.7 | 1.06-9.44 | 3.4 | 1.67-5.79 | 1.6 | 0.22-3.58* | 1.2 | 0.13-2.77* | 3.1 | 1.72-4.58 | 2.7 | 0.00-7.42* |

© 2020 Bajema KL et al. JAMA Internal Medicine.
| Jurisdiction | Collection Dates | Number of Specimens | Overall | Male | Female | Age <18 | Age 18-49 | Age 50-64 | Age ≥65 | Metro Counties | Non-metro Counties |
|-------------|------------------|---------------------|---------|------|--------|---------|-----------|-----------|---------|----------------|--------------------|
| WI          | 08/12 - 08/27/2020 | 838                 | 3.3     | 2.03-4.72 | 2.1 | 0.74-3.74 | 4.5 | 2.26-6.81 | 1.4 | 0.00-3.84* | 1.92-7.18 | 3.8 | 1.50-6.22 | 2.2 | 0.00-5.29* | 3.6 | 2.07-5.24 |
| WV          | 08/13 - 08/27/2020 | 637                 | 2.2     | 0.52-4.90* | 2.5 | 0.22-7.73* | 1.9 | 0.30-4.49* | ❍ | ❍ | ❍ | ❍ | ❍ | ❍ | ❍ | ❍ |
| WY          | 08/13 - 08/24/2020 | 86                  | 0.8     | 0.00-3.11* | ❍ | ❍ | ❍ | ❍ | ❍ | ❍ | ❍ | ❍ | ❍ | ❍ | ❍ | ❍ |

†† No specimens were collected for the subgroup in period 2. Estimates are not shown.
† Because of small cell size (n < 75) for the subgroup in period 2, estimates are not shown.
* The confidence interval surrounding the estimate is large (i.e., high variance) relative to the estimate itself (RHWCI > 1.0). Associated point estimates should be interpreted with caution.
** No positive specimens were reported for the subgroup in period 2; confidence intervals were computed separately using Clopper-Pearson Exact method.
*** No specimen records received and analyzed for the jurisdiction in period 2.
NA indicates jurisdictions that do not have non-metro counties.
eTable 5. Overall, sex-, age-, and metropolitan/nonmetropolitan-stratified SARS-CoV-2 prevalence estimates and 95% confidence intervals by jurisdiction during period 3

| Jurisdiction | Collection Dates | Number of Specimens | Overall | C.I. | Male | C.I. | Female | C.I. | Age <18 | C.I. | Age 18-49 | C.I. | Age 50-64 | C.I. | Age ≥65 | C.I. | Metro Counties | C.I. | Non-metro Counties | C.I. |
|--------------|------------------|---------------------|---------|------|------|------|--------|------|---------|------|-----------|------|-----------|------|---------|------|------------------|------|----------------------|------|
| AK           | 08/26 - 09/09/2020 | 610                 | 1.0     | 0.24-2.17* | 1.0   | 0.00-3.19* | 1.1   | 0.14-2.50* | t    | 1.6     | 0.00-3.78* | 1.4   | 0.00-3.30* | 0.5  | 0.00-1.86* | 1.5  | 0.35-3.12* | 0.1  | 0.00-1.21       |
| AL           | 08/26 - 09/08/2020 | 955                 | 9.9     | 7.19-12.79 | 7.7   | 4.19-12.18 | 11.9  | 8.24-16.73 | t    | 11.6    | 7.67-16.19 | 7.0   | 3.59-10.48 | 3.4  | 1.64-5.60 | 9.3  | 6.61-12.49 | 11.7 | 4.40-18.43      |
| AR           | 08/24 - 09/08/2020 | 992                 | 4.9     | 3.50-6.41 | 4.3   | 2.36-6.62 | 5.6   | 3.54-7.74 | 7.8  | 3.61-11.73 | 3.6   | 1.69-5.91 | 4.3  | 1.72-7.34 | 5.1  | 2.23-8.24 | 5.6  | 3.79-7.66 | 3.8  | 1.97-5.58       |
| AZ           | 08/26 - 09/09/2020 | 1,030               | 4.9     | 3.05-7.11 | 3.9   | 0.70-8.35 | 5.8   | 4.39-7.56 | t    | 9.3     | 5.90-13.18 | 5.4   | 0.57-13.06* | t    | 5.1     | 3.15-7.48 | t    |                   |
| CA           | 08/28 - 09/09/2020 | 983                 | 6.0     | 4.20-7.82 | 6.0   | 3.60-9.10 | 6.0   | 3.79-8.83 | 7.6  | 3.88-11.43 | 6.3   | 3.20-9.78 | 4.5  | 1.97-7.77 | 4.0  | 1.56-7.38 | 6.0  | 4.25-7.89 | t    |                   |
| CO           | 08/24 - 09/04/2020 | 1,025               | 3.6     | 2.31-5.09 | 4.4   | 2.14-7.06 | 2.8   | 1.52-4.25 | 4.0  | 1.83-6.38 | 3.6   | 1.24-6.44 | 3.1  | 1.09-5.24 | 3.4  | 1.08-5.82 | 4.1  | 2.64-5.82 | t    |                   |
| CT           | 08/26 - 09/04/2020 | 983                 | 4.3     | 2.90-5.69 | 4.6   | 2.53-6.63 | 4.1   | 2.33-5.90 | 6.9  | 3.91-10.32 | 5.1   | 2.68-7.98 | 2.6  | 0.67-5.10 | 1.4  | 0.00-3.08 | 4.6  | 3.06-5.99 | t    |                   |
| DC           | 08/27 - 09/10/2020 | 643                 | 5.0     | 2.83-7.55 | 5.7   | 2.47-10.11 | 4.3   | 1.98-7.19 | t    | 5.7     | 2.64-9.24 | 4.9   | 1.52-9.31 | 3.3  | 0.94-6.48 | 5.0  | 2.83-7.55 | NA   |                   |
| DE           | 08/26 - 09/10/2020 | 914                 | 4.5     | 2.42-7.12 | 3.9   | 1.13-7.88 | 5.0   | 2.29-8.77 | t    | 5.3     | 2.73-8.69 | 2.9   | 0.80-5.42 | 1.1  | 0.23-2.28 | 4.5  | 2.42-7.12 | NA   |                   |
| FL           | 08/27 - 09/09/2020 | 981                 | 5.7     | 3.93-7.49 | 6.0   | 3.12-9.09 | 5.3   | 3.37-7.70 | 3.8  | 1.11-6.51 | 9.3   | 5.38-13.53 | 5.1  | 2.22-8.97 | 0.7  | 0.00-1.87* | 5.9  | 4.07-7.74 | t    |                   |
| GA           | 08/25 - 09/10/2020 | 1,020               | 8.7     | 6.69-11.14 | 8.2   | 5.51-11.58 | 9.2   | 6.52-12.51 | 13.4  | 8.84-18.51 | 6.8   | 3.83-10.60 | 9.3  | 5.30-13.99 | 5.5  | 2.58-9.08 | 9.1  | 7.02-11.61 | 6.7  | 1.99-12.62 |       |
| HI           | 08/28 - 09/09/2020 | 12                  | t       | t       | t       | t       | t       | t       | t       | t       | t       | t       | t       | t       | t       | t       |                   |
| IA           | 08/25 - 09/10/2020 | 1,006               | 8.4     | 6.15-10.74 | 7.6   | 4.68-11.00 | 9.3   | 5.93-12.85 | t    | 9.8     | 6.72-12.99 | 8.7   | 5.66-12.16 | 3.5  | 1.20-6.02 | 10.1 | 6.52-13.73 | 5.9  | 3.68-8.30       |
| ID           | 08/26 - 09/10/2020 | 790                 | 5.7     | 2.90-9.70 | 8.0   | 2.67-15.94 | 3.4   | 1.86-5.61 | t    | 7.0     | 3.23-12.14 | 4.4   | 1.56-8.13 | 3.4  | 0.88-6.90 | 7.6  | 3.60-13.51 | 1.8  | 0.00-5.93*      |
| IL           | 08/26 - 09/03/2020 | 979                 | 5.6     | 3.90-7.67 | 5.0   | 3.04-7.34 | 6.1   | 3.50-9.83 | 9.6   | 5.89-13.41 | 3.1   | 1.28-5.33 | 6.7  | 1.86-14.30 | 4.9  | 2.30-7.94 | 5.6  | 4.05-7.24 | t    |                   |
| Jurisdiction | Collection Dates   | Number of Specimens | Overall | Male | Female | Age <18 | Age 18-49 | Age 50-64 | Age ≥65 | Metro Counties | Non-metro Counties |
|--------------|--------------------|---------------------|---------|------|--------|---------|-----------|-----------|---------|----------------|------------------|
| IN           | 08/26 - 09/09/2020 | 984                 | 2.4     | 1.36-3.52 | 2.0 | 0.36-4.09 | 2.8 | 1.47-4.46 | †   | 3.8 | 1.81-5.97 | 3.0 | 0.63-6.29 | 1.7 | 0.16-3.93* | 2.6 | 1.46-3.91 †   |
| KS           | 08/24 - 09/03/2020 | 1,025               | 2.9     | 1.57-3.41 | 1.9 | 0.61-3.44 | 3.9 | 1.90-6.39 | 1.9 | 0.57-3.62 | 3.4 | 0.92-6.49 | 3.9 | 1.51-6.77 | 1.9 | 0.29-4.68 | 2.6 | 1.59-3.94 3.3 | 0.45-6.62   |
| KY           | 08/26 - 09/08/2020 | 983                 | 3.1     | 1.91-4.33 | 2.6 | 1.03-4.48 | 3.5 | 1.97-5.23 | 2.3 | 0.45-4.50 | 3.5 | 1.40-5.84 | 4.0 | 1.52-6.54 | 2.0 | 0.30-3.95 | 3.9 | 2.38-5.67 1.9 | 0.44-3.70   |
| LA           | 08/26 - 09/09/2020 | 1,001               | 8.6     | 6.65-11.30 | 6.3 | 3.49-9.56 | 10.8 | 7.40-15.35 | 8.3 | 4.25-14.50 | 9.9 | 6.04-14.73 | 7.9 | 4.55-12.36 | 6.5 | 3.35-11.00 | 10.1 | 7.91-12.49 †   |
| MA           | 08/27 - 09/05/2020 | 981                 | 3.6     | 2.36-5.08 | 4.5 | 2.28-6.98 | 2.8 | 1.39-4.46 | 6.3 | 2.09-9.89 | 2.1 | 0.39-4.58 | 7.0 | 3.46-10.67 | 1.3 | 0.00-3.19* | 3.6 | 2.36-5.08 † †   |
| MD           | 08/26 - 09/08/2020 | 980                 | 7.9     | 5.72-10.35 | 9.9 | 6.23-14.31 | 6.0 | 3.52-9.00 | 15.6 | 7.84-24.49 | 6.2 | 3.54-9.16 | 7.7 | 4.70-11.14 | 1.4 | 0.00-3.31* | 8.1 | 5.83-10.56 †   |
| ME           | 08/26 - 09/10/2020 | 759                 | 1.5     | 0.44-3.22 | 1.5 | 0.43-2.78 | 1.6 | 0.00-4.96* †   | 0.3 | 0.00-1.19* | 3.2 | 1.05-6.49 | 0.3 | 0.00-1.36* | 2.4 | 0.68-5.29 0.2 | 0.00-0.88*   |
| MI           | 08/26 - 09/03/2020 | 976                 | 3.4     | 2.16-4.95 | 3.6 | 1.57-5.86 | 3.2 | 1.74-4.89 | 5.2 | 2.25-8.28 | 3.3 | 1.09-6.51 | 2.9 | 1.00-5.36 | 1.9 | 0.34-3.81 | 3.8 | 2.40-5.44 1.4 | 0.00-4.59*   |
| MN           | 08/26 - 09/08/2020 | 974                 | 9.2     | 6.71-11.95 | 6.9 | 4.05-10.79 | 11.5 | 7.97-15.79 | 4.7 | 0.51-11.63* | 11.8 | 7.88-17.03 | 10.6 | 5.42-17.43 | 7.4 | 3.71-12.79 | 8.8 | 6.81-11.07 †   |
| MO           | 08/24 - 09/10/2020 | 1,024               | 2.9     | 1.74-4.17 | 2.3 | 0.79-3.95 | 3.5 | 1.88-5.22 | 5.8 | 3.02-8.96 | 2.7 | 0.85-5.12 | 2.0 | 0.33-3.86 | 0.6 | 0.00-1.70* | 3.2 | 1.92-4.70 2.2 | 0.00-4.49   |
| MS           | 08/26 - 09/10/2020 | 987                 | 8.4     | 4.89-12.73 | 4.8 | 2.17-8.23 | 11.8 | 5.49-20.00 | †   | 9.9 | 5.73-14.11 | 4.0 | 1.70-7.26 | 6.4 | 2.79-11.09 | 6.6 | 3.56-10.73 9.9 | 4.23-18.04   |
| MT           | 08/24 - 09/09/2020 | 518                 | 0.9     | 0.23-1.82 | 1.0 | 0.00-2.33* | 0.9 | 0.00-1.97 | †   | 1.2 | 0.00-2.93* | 0.4 | 0.00-1.42* | 2.2 | 0.00-5.10 | 2.0 | 0.32-4.33 0.4 | 0.00-1.06*   |
| NC           | 08/26 - 09/09/2020 | 982                 | 3.8     | 2.33-5.26 | 2.8 | 1.31-4.65 | 4.7 | 2.57-7.26 | 6.5 | 3.20-9.94 | 2.9 | 0.96-5.52 | 3.1 | 0.98-5.53 | 3.0 | 0.91-5.74 | 3.9 | 2.40-5.53 3.3 | 0.96-6.91   |
| ND           | 08/26 - 09/09/2020 | 109                 | 0.2     | 0.00-0.99* †   | 0.5 | 0.00-2.04* †   | †   | †   | †   | †   | †   | 0.5 | 0.00-1.99* †   |
| NE           | 08/24 - 09/10/2020 | 938                 | 6.3     | 4.47-8.27 | 5.1 | 2.85-7.73 | 7.4 | 4.26-10.72 | 9.8 | 4.14-15.92 | 6.2 | 3.48-9.55 | 5.6 | 3.26-8.54 | 1.6 | 0.29-3.08 | 8.8 | 6.28-11.71 1.5 | 0.00-3.54*   |
| NH           | 08/26 - 09/03/2020 | 1,147               | 1.6     | 0.73-2.84 | 1.6 | 0.19-3.90* | 1.7 | 0.76-2.86 | †   | 1.8 | 0.59-3.33 | 1.2 | 0.38-2.27 | 1.0 | 0.00-2.22* | 2.3 | 0.99-4.16 0.5 | 0.00-1.54*   |
| NJ           | 08/26 - 09/07/2020 | 944                 | 12.8    | 10.49-15.35 | 11.6 | 8.27-15.28 | 14.0 | 10.83-17.51 | 17.4 | 12.23-22.94 | 12.2 | 8.35-16.66 | 14.5 | 9.89-19.19 | 5.4 | 2.34-9.10 12.8 | 10.49-15.35 NA |

© 2020 Bajema KL et al. JAMA Internal Medicine.
| Jurisdiction | Collection Dates | Number of Specimens | Overall | Male | Female | Age <18 | Age 18-49 | Age 50-64 | Age ≥65 | Metro Counties | Non-metro Counties |
|--------------|------------------|---------------------|---------|------|--------|---------|----------|----------|--------|----------------|-------------------|
| NM           | 08/25 - 09/08/2020 | 985                | 3.7     | 2.28-5.55 | 3.2 | 1.11-6.06 | 4.1 | 2.27-6.36 | 2.0 | 0.00-4.97* | 5.8 | 3.00-9.35 | 2.5 | 0.88-4.59 | 2.3 | 0.50-5.09* | 4.1 | 2.46-6.06 | 2.9 | 0.60-5.80* |
| NV           | 08/27 - 08/29/2020 | 980                | 6.5     | 4.63-8.58 | 6.5 | 3.71-9.79 | 6.6 | 4.38-8.80 | 5.4 | 2.55-8.62 | 7.1 | 4.02-10.40 | 6.7 | 3.59-10.15 | 6.5 | 2.42-12.23 | 6.9 | 4.88-8.88 |
| NY           | 08/26 - 09/10/2020 | 1,043              | 19.5    | 16.88-22.38 | 18.7 | 14.92-22.86 | 20.3 | 16.36-24.53 | 18.2 | 14.05-23.29 | 23.0 | 17.51-29.15 | 20.2 | 15.04-25.20 | 10.8 | 7.22-14.96 | 20.7 | 17.89-23.78 | 4.0 | 0.00-9.67* |
| OH           | 08/27 - 09/10/2020 | 983                | 5.0     | 3.17-7.14 | 5.5 | 2.59-8.84 | 4.6 | 2.03-7.39 | 10.2 | 3.42-17.85 | 4.2 | 1.93-7.02 | 4.0 | 1.55-7.12 | 1.1 | 0.00-2.78* | 4.6 | 2.74-6.71 | 6.8 | 1.81-13.43 |
| OK           | 08/24 - 09/01/2020 | 979                | 5.4     | 3.83-7.29 | 5.5 | 2.88-8.23 | 5.4 | 3.16-7.82 | 9.5 | 5.15-14.26 | 4.9 | 2.18-8.13 | 3.8 | 1.72-6.52 | 2.1 | 0.00-4.53* | 6.3 | 4.02-8.74 | 3.8 | 1.53-6.28 |
| OR           | 08/26 - 09/10/2020 | 968                | 1.9     | 0.92-2.94 | 2.3 | 0.70-4.06 | 1.5 | 0.33-2.97 | 1.6 | 0.00-3.98* | 2.6 | 0.77-5.03 | 1.1 | 0.00-3.16* | 1.4 | 0.29-3.14* | 1.8 | 0.83-2.96 | 2.2 | 0.00-5.85* |
| PA           | 08/26 - 09/09/2020 | 845                | 9.5     | 6.58-13.56 | 14.5 | 9.30-22.42 | 4.7 | 2.58-7.65 | † | 15.2 | 12.09-18.46 | 7.5 | 3.26-12.56 | 1.8 | 0.00-4.68* | 10.7 | 7.34-15.17 | 0.6 | 0.00-2.67* |
| PR           | 08/24 - 09/03/2020 | 980                | 2.5     | 1.36-3.76 | 3.3 | 1.31-5.77 | 1.8 | 0.73-3.08 | 1.9 | 0.34-4.21* | 3.3 | 1.13-6.01 | 0.4 | 0.00-1.44* | 3.5 | 1.26-6.15 | 2.7 | 1.45-3.96 | † |
| RI           | 08/27 - 09/10/2020 | 786                | 3.1     | 1.73-4.64 | 3.5 | 1.34-6.23 | 2.6 | 1.07-4.33 | † | 3.5 | 1.39-5.84 | 3.9 | 1.44-6.85 | 1.8 | 0.35-4.10 | 3.1 | 1.73-6.44 | NA |
| SC           | 08/26 - 09/10/2020 | 927                | 7.2     | 5.12-9.57 | 6.5 | 3.53-9.76 | 7.8 | 5.25-11.28 | 6.7 | 2.02-12.97 | 10.1 | 5.97-14.42 | 4.8 | 2.25-7.90 | 3.3 | 1.10-6.13 | 7.2 | 4.73-9.95 | 7.0 | 3.21-11.48 |
| SD           | 08/26 - 09/10/2020 | 97                 | 0.7     | 0.00-2.47* | 1.3 | 0.00-4.89* | † | † | † | † | † | † | † | † | † | † | † |
| TN           | 08/25 - 09/08/2020 | 950                | 5.4     | 3.62-7.31 | 5.6 | 3.18-8.52 | 5.2 | 2.96-7.74 | 5.3 | 2.05-9.01 | 7.0 | 3.81-11.03 | 3.5 | 1.11-6.07 | 4.0 | 1.59-6.91 | 6.3 | 4.13-8.58 | 2.4 | 0.39-5.05* |
| TX           | 08/25 - 09/02/2020 | 979                | 5.8     | 4.04-7.92 | 6.8 | 4.08-10.31 | 4.9 | 2.63-7.54 | 6.3 | 2.92-10.13 | 6.1 | 3.00-9.69 | 5.8 | 2.66-9.90 | 3.8 | 1.61-6.90 | 6.3 | 4.43-8.49 | 1.9 | 0.00-4.75* |
| UT           | 08/24 - 09/08/2020 | 1,104              | 4.9     | 2.82-7.67 | 6.1 | 2.77-10.49 | 3.8 | 1.77-6.77 | † | 4.3 | 2.25-6.76 | 6.5 | 3.68-10.08 | 2.3 | 0.58-4.20 | 5.4 | 3.09-8.58 | 0.7 | 0.00-2.07* |
| VA           | 08/26 - 09/08/2020 | 1,007              | 3.5     | 1.97-5.26 | 3.2 | 1.09-5.79 | 3.8 | 1.57-6.63 | † | 4.9 | 2.28-7.84 | 3.2 | 1.04-5.62 | 1.8 | 0.31-3.59 | 3.3 | 1.77-5.31 | 4.9 | 0.00-11.46* |
| VT           | 08/26 - 09/10/2020 | 485                | 0.4     | 0.00-0.94* | 0.4 | 0.00-1.39* | 0.4 | 0.00-1.09* | † | 0.0 | 0.00-1.86** | 0.5 | 0.00-1.92* | 1.5 | 0.00-4.37* | 0.6 | 0.00-1.96* | 0.3 | 0.00-0.85* |
| WA           | 08/25 - 09/10/2020 | 820                | 4.5     | 2.63-6.94 | 4.6 | 1.74-8.62 | 4.5 | 2.08-7.85 | 6.0 | 2.36-9.99 | 5.6 | 1.95-10.80 | 2.5 | 0.71-4.76 | 1.7 | 0.16-3.57* | 4.5 | 2.44-7.05 | † |

© 2020 Bajema KL et al. JAMA Internal Medicine.
| Jurisdiction | Collection Dates | Number of Specimens | Overall | % | C.I. | Male | % | C.I. | Female | % | C.I. | Age <18 | % | C.I. | Age 18-49 | % | C.I. | Age 50-64 | % | C.I. | Age ≥65 | % | C.I. |
|--------------|------------------|---------------------|---------|---|-----|------|---|-----|--------|---|-----|--------|---|-----|---------|---|-----|---------|---|-----|---------|---|-----|
| WI           | 08/25 - 09/10/2020 | 976                | 2.6     | 1.48-3.95 | 2.2 | 0.84-3.85 | 3.0 | 1.30-4.93 | 0.8 | 0.00-3.10* | 4.2 | 1.78-7.03 | 2.3 | 0.44-4.33 | 1.4 | 0.20-2.85 | 2.4 | 1.20-3.66 | 3.2 | 0.62-6.47 |
| WV           | 08/26 - 09/10/2020 | 1,128              | 1.5     | 0.78-2.38 | 1.5 | 0.50-2.67 | 1.5 | 0.56-2.79 | †  | †   | †      | †  | †   | †      | †  | †   | †      | †  | †   | †      |
| WY           | 08/24 - 09/09/2020 | 70                 | †       | †   | †   | †   | †   | †   | †   | †   | †   | †   | †   | †   | †   | †   | †   |

† † No specimens were collected for the subgroup in period 3. Estimates are not shown.
† † Because of small cell size (n < 75) for the subgroup in period 3, estimates are not shown.
* The confidence interval surrounding the estimate is large (i.e., high variance) relative to the estimate itself (RHWCI > 1.0). Associated point estimates should be interpreted with caution.
** No positive specimens were reported for the subgroup in period 3; confidence intervals were computed separately using Clopper-Pearson Exact method.
*** No specimen records received and analyzed for the jurisdiction in period 3.
NA indicates jurisdictions that do not have non-metro counties.
eTable 6. Overall, sex-, age-, and metropolitan/nonmetropolitan-stratified SARS-CoV-2 prevalence estimates and 95% confidence intervals by jurisdiction during period 4

| Jurisdiction | Collection Dates | Number of Specimens | Overall % | C.I. | Male % | C.I. | Female % | C.I. | Age <18 % | C.I. | Age 18-49 % | C.I. | Age 50-64 % | C.I. | Age ≥65 % | C.I. | Metro Counties % | C.I. | Non-metro Counties % | C.I. |
|--------------|------------------|---------------------|-----------|------|--------|------|----------|------|-----------|------|-------------|------|-------------|------|------------|------|-------------------|------|-------------------|------|
| AK           | 09/09 - 09/18/2020 | 681                 | 0.4       | 0.11-0.82 | 0.2 | 0.00-0.95* | 0.6 | 0.12-1.23* | †    | 0.0 | 0.00-1.96** | 2.1 | 0.56-4.25 | 0.0 | 0.00-1.58** | 0.5 | 0.09-1.14* | 0.2 | 0.00-0.62* |
| AL           | 09/09 - 09/18/2020 | 905                 | 8.7       | 6.19-11.31 | 7.4 | 3.95-11.21 | 9.9 | 6.44-13.76 | 16.1 | 8.47-24.39 | 8.1 | 4.76-11.73 | 4.6 | 2.12-7.92 | 4.9 | 2.29-7.99 | 7.3 | 4.94-10.16 | 13.2 | 7.46-19.71 |
| AR           | 09/09 - 09/18/2020 | 990                 | 6.3       | 4.60-8.03  | 6.8 | 4.22-9.26  | 5.7 | 3.75-8.02  | 8.6 | 4.20-13.10 | 6.9 | 3.82-9.94  | 5.2 | 2.49-8.54 | 2.6 | 0.64-4.99 | 5.9 | 3.77-8.35 | 6.9 | 4.35-9.62 |
| AZ           | 09/09 - 09/23/2020 | 1,208              | 5.4       | 3.08-8.52  | 2.8 | 0.00-6.62* | 8.0 | 4.34-12.86 | †    | 9.6 | 5.03-15.86 | 4.4 | 1.07-9.09 | 0.1 | 0.00-0.42* | 4.6 | 2.94-6.88 | †   | 3.20-6.97 |
| CA           | 09/10 - 09/16/2020 | 979                 | 4.9       | 3.17-6.85  | 5.9 | 3.22-8.67  | 4.0 | 2.03-6.21  | 8.1 | 4.35-12.01 | 4.7 | 1.83-8.13  | 3.6 | 1.18-6.65 | 2.1 | 0.38-4.66* | 5.0 | 3.20-6.97 | †   | 3.17-6.85  |
| CO           | 09/09 - 09/18/2020 | 1,032              | 3.3       | 1.90-4.92  | 2.7 | 0.91-5.05  | 3.9 | 1.76-6.53  | 4.5 | 1.30-9.81  | 3.6 | 1.33-6.34 | 1.9 | 0.51-3.45 | 2.3 | 0.65-4.23 | 3.3 | 1.95-4.79 | †   | 1.90-4.92  |
| CT           | 09/09 - 09/14/2020 | 982                 | 3.1       | 2.06-4.37  | 3.2 | 1.76-4.96  | 3.0 | 1.59-6.41  | 4.1 | 1.50-7.20  | 2.0 | 0.52-3.86 | 4.3 | 1.74-7.27 | 3.1 | 0.83-5.63 | 2.9 | 1.86-4.04 | †   | 2.06-4.37  |
| DC           | 09/08 - 09/24/2020 | 976                 | 6.5       | 4.47-8.29  | 7.1 | 4.36-9.97  | 5.9 | 3.49-8.57  | 7.5 | 2.70-12.52 | 6.0 | 3.31-9.02 | 8.7 | 4.43-12.74 | 4.1 | 1.82-6.63 | 6.5 | 4.47-8.29 | NA  | 1.82-6.63 |
| DE           | 09/09 - 09/24/2020 | 980                 | 7.5       | 4.89-10.50 | 7.6 | 3.93-11.89 | 7.4 | 4.09-11.24 | †    | 8.6 | 4.62-12.73 | 2.9 | 0.93-5.20 | 3.2 | 1.38-5.60 | 7.5 | 4.89-10.50 | NA  | 1.38-5.60 |
| FL           | 09/11 - 09/11/2020 | 979                 | 8.5       | 6.55-10.68 | 9.3 | 6.12-12.83 | 7.8 | 5.27-10.68 | 13.0 | 8.08-18.74 | 10.0 | 6.19-13.81 | 6.5 | 3.37-10.60 | 3.0 | 1.04-5.76 | 8.8 | 6.78-10.99 | †   | 3.37-10.60 |
| GA           | 09/09 - 09/18/2020 | 1,100               | 13.0      | 10.51-15.79 | 14.0 | 9.71-18.00 | 12.1 | 8.45-15.24 | 18.7 | 13.95-23.87 | 15.1 | 10.33-20.63 | 5.4 | 2.75-8.90 | 6.3 | 2.78-10.57 | 12.7 | 10.07-15.50 | 14.7 | 7.30-24.22 |
| HI           | 09/08 - 09/22/2020 | 516                 | 0.8       | 0.00-2.18* | 1.4 | 0.00-3.97* | 0.3 | 0.00-1.22* | †    | 1.9 | 0.00-5.10* | 0.0 | 0.00-2.31** | 0.3 | 0.00-1.77** | 1.0 | 0.00-2.67* | †   | 0.00-2.18* |
| IA           | 09/09 - 09/24/2020 | 977                 | 7.6       | 5.56-10.02 | 5.9 | 3.27-9.28  | 9.2 | 6.43-12.32 | †    | 11.3 | 7.24-15.02 | 9.9 | 6.85-13.12 | 3.3 | 1.32-5.78 | 9.1 | 6.37-12.71 | 5.4 | 3.13-8.11 |
| ID           | 09/08 - 09/18/2020 | 732                 | 5.2       | 2.74-8.46  | 2.6 | 1.10-4.67  | 7.8 | 3.13-14.14 | †    | 4.1 | 1.59-7.42  | 7.8 | 3.83-12.51 | 1.6 | 0.00-3.49* | 5.9 | 2.51-10.32 | 3.8 | 1.07-8.35 |
| IL           | 09/08 - 09/17/2020 | 992                 | 4.5       | 3.10-6.07  | 6.2 | 3.88-8.91  | 2.9 | 1.67-4.44  | 5.7 | 2.87-8.71  | 3.5 | 1.33-6.13 | 6.9 | 3.73-10.43 | 2.6 | 0.72-5.17 | 5.1 | 3.50-6.86 | †   | 3.10-6.07  |

© 2020 Bajema KL et al. JAMA Internal Medicine.
| Jurisdiction | Collection Dates | Number of Specimens | Overall | Male | Female | Age <18 | Age 18-49 | Age 50-64 | Age ≥65 | Metro Counties | Non-metro Counties |
|--------------|------------------|---------------------|---------|------|--------|---------|---------|---------|--------|----------------|-------------------|
| IN           | 09/09 - 09/23/2020 | 1,155 | 4.0 | 1.44-8.79 | 5.5 | 0.72-15.45 | 2.5 | 1.57-3.55 | † | 2.6 | 1.39-3.88 | 3.0 | 0.98-5.86 | 2.8 | 0.77-5.05 | 5.1 | 1.74-11.20 | 0.2 | 0.00-0.95* |
| KS           | 09/09 - 09/19/2020 | 1,007 | 3.5 | 2.31-4.84 | 3.4 | 1.77-5.58 | 3.5 | 1.82-5.36 | 5.0 | 2.04-8.01 | 3.6 | 1.67-6.05 | 2.3 | 0.39-4.48 | 2.3 | 0.45-4.48 | 3.7 | 2.36-5.12 | 3.0 | 0.83-5.44 |
| KY           | 09/09 - 09/18/2020 | 980 | 3.6 | 2.33-5.21 | 5.0 | 2.67-7.52 | 2.4 | 1.12-4.02 | 4.1 | 1.14-7.60 | 4.8 | 2.22-7.63 | 2.5 | 0.62-4.74 | 1.5 | 0.00-3.42* | 5.2 | 3.14-7.42 | 1.5 | 0.11-3.50* |
| LA           | 09/09 - 09/19/2020 | 952 | 12.5 | 10.02-15.61 | 11.8 | 8.05-16.83 | 13.1 | 9.57-16.89 | 15.1 | 9.78-21.76 | 15.5 | 10.87-21.50 | 8.4 | 4.52-12.90 | 4.8 | 1.91-8.22 | 12.3 | 9.59-15.52 | 13.6 | 8.06-20.82 |
| MA           | 09/09 - 09/15/2020 | 988 | 3.7 | 2.23-5.16 | 3.1 | 1.28-5.55 | 4.2 | 2.30-6.44 | 5.3 | 2.31-8.46 | 5.2 | 2.27-8.41 | 1.4 | 0.00-3.23 | 0.6 | 0.00-1.95* | 3.7 | 2.26-5.23 | † |
| MD           | 09/10 - 09/23/2020 | 1,242 | 10.2 | 7.91-12.68 | 12.7 | 9.66-15.94 | 7.8 | 4.76-11.01 | 11.5 | 5.26-18.50 | 13.5 | 9.92-17.33 | 6.4 | 4.06-8.95 | 3.6 | 1.81-5.81 | 10.3 | 8.10-12.99 | † |
| ME           | 09/08 - 09/24/2020 | 987 | 0.5 | 0.09-0.87 | 0.2 | 0.00-0.73* | 0.7 | 0.15-1.41 | † | 0.8 | 0.00-1.66 | 0.4 | 0.00-1.10* | 0.4 | 0.00-1.09* | 0.8 | 0.16-1.47 | 0.0 | 0.00-1.35** |
| MI           | 09/08 - 09/22/2020 | 980 | 3.7 | 2.54-4.93 | 2.4 | 0.87-4.24 | 4.9 | 2.86-6.99 | 7.3 | 3.80-11.09 | 3.3 | 1.37-5.55 | 1.9 | 0.35-3.83 | 1.9 | 0.00-3.96 | 4.2 | 2.91-5.76 | 1.0 | 0.00-2.68* |
| MN           | 09/09 - 09/23/2020 | 1,033 | 8.0 | 4.74-11.43 | 8.5 | 3.90-13.28 | 7.5 | 3.69-12.69 | 10.6 | 1.68-21.27 | 8.7 | 4.27-14.25 | 6.4 | 3.18-10.90 | 4.0 | 1.76-6.66 | 6.5 | 4.67-8.64 | † |
| MO           | 09/08 - 09/24/2020 | 1,031 | 3.5 | 2.15-5.01 | 3.1 | 1.49-5.47 | 3.9 | 2.00-6.07 | 5.1 | 2.34-8.57 | 4.2 | 1.33-7.48 | 2.3 | 0.64-4.18 | 1.2 | 0.00-3.16* | 3.5 | 2.14-5.08 | 3.8 | 0.55-7.67 |
| MS           | 09/09 - 09/22/2020 | 980 | 7.9 | 5.35-10.87 | 7.6 | 4.42-11.42 | 8.2 | 4.35-12.81 | † | 11.9 | 6.94-17.26 | 7.6 | 3.81-11.71 | 6.2 | 2.84-10.21 | 7.7 | 4.67-11.32 | 8.0 | 4.23-12.46 |
| MT           | 09/09 - 09/23/2020 | 508 | 2.2 | 0.67-4.38 | 2.0 | 0.31-4.49 | 2.5 | 0.33-6.41* | † | 0.8 | 0.00-3.09* | 3.3 | 0.73-7.47 | 2.3 | 0.00-5.39* | 2.1 | 0.44-4.19 | 2.3 | 0.17-5.31* |
| NC           | 09/09 - 09/17/2020 | 925 | 6.8 | 4.83-8.87 | 6.9 | 3.93-10.07 | 6.7 | 4.38-9.36 | 10.1 | 5.68-16.04 | 8.4 | 4.58-12.59 | 4.4 | 1.76-7.37 | 0.4 | 0.00-1.39* | 6.7 | 4.58-8.84 | 7.0 | 3.40-12.06 |
| ND           | 09/09 - 09/24/2020 | 113 | 1.2 | 0.00-3.40* | † | 2.4 | 0.00-6.98* | † | † | † | † | 0.0 | 0.00-4.40** | † |
| NE           | 09/09 - 09/18/2020 | 976 | 6.7 | 4.80-8.88 | 6.5 | 3.76-9.77 | 7.0 | 4.24-10.20 | † | 5.1 | 2.82-7.46 | 7.5 | 4.43-11.16 | 6.0 | 3.21-9.08 | 8.3 | 5.64-10.96 | 3.9 | 0.96-8.31 |
| NH           | 09/09 - 09/17/2020 | 1,034 | 0.7 | 0.26-1.32 | 0.9 | 0.05-1.86 | 0.6 | 0.06-1.35 | † | 1.1 | 0.18-2.18 | 0.6 | 0.00-1.63* | 1.1 | 0.00-2.67* | 1.1 | 0.32-1.83 | 0.2 | 0.00-0.83* |
| NJ           | 09/09 - 09/23/2020 | 1,050 | 15.1 | 12.65-17.63 | 17.9 | 14.25-21.72 | 12.4 | 9.53-15.58 | 18.1 | 12.68-23.29 | 18.9 | 14.75-23.77 | 12.0 | 8.40-15.50 | 4.8 | 2.09-7.82 | 15.1 | 12.65-17.63 | NA |

© 2020 Bajema KL et al. JAMA Internal Medicine.
| Jurisdiction | Collection Dates | Number of Specimens | Overall | Male | Female | Age <18 | Age 18-49 | Age 50-64 | Age ≥65 | Metro Counties | Non-metro Counties |
|-------------|-----------------|---------------------|---------|------|--------|--------|----------|----------|--------|---------------|------------------|
| NM          | 09/08 - 09/24/2020 | 1,014               | 2.4     | 1.19-3.65 | 2.1 | 0.63-4.23 | 2.6 | 1.30-4.35 | 4.0 | 1.13-8.35 | 1.7 | 0.42-3.73* | 1.7 | 0.23-3.49* | 2.4 | 0.45-5.13* | 1.9 | 0.91-3.15 | 3.3 | 0.99-6.39 |
| NV          | 09/09 - 09/12/2020 | 979                 | 7.8     | 5.90-9.99 | 8.3 | 5.40-11.77 | 7.2 | 4.86-9.99 | 6.3 | 3.13-9.91 | 9.8 | 5.96-14.45 | 9.2 | 5.70-13.38 | 2.5 | 0.78-4.69 | 8.6 | 6.51-11.02 |
| NY          | 09/11 - 09/24/2020 | 1,168               | 17.0    | 14.72-19.23 | 16.0 | 12.51-19.44 | 18.0 | 14.96-21.24 | 21.4 | 16.82-26.39 | 17.2 | 13.15-21.68 | 16.5 | 12.10-20.83 | 11.2 | 7.66-14.59 | 18.3 | 15.83-20.69 |
| OH          | 09/10 - 09/22/2020 | 978                 | 2.8     | 1.69-4.16 | 3.1 | 1.26-5.21 | 2.6 | 1.00-4.62 | 4.9 | 0.85-9.91 | 2.0 | 0.44-3.77 | 2.1 | 0.36-4.05 | 3.1 | 1.15-5.27 | 2.8 | 1.66-4.33 | 2.9 | 0.00-7.38* |
| OK          | 09/09 - 09/18/2020 | 980                 | 5.0     | 3.44-6.54 | 3.7 | 1.68-6.04 | 6.2 | 3.93-8.52 | 7.1 | 3.68-10.91 | 5.5 | 2.77-8.59 | 3.8 | 1.44-6.85 | 1.6 | 0.00-3.65* | 5.4 | 3.65-7.48 | 4.2 | 2.02-6.71 |
| OR          | 09/08 - 09/22/2020 | 971                 | 2.6     | 1.51-4.06 | 2.9 | 1.05-5.21 | 2.4 | 0.93-4.18 | 5.2 | 1.65-9.92 | 1.7 | 0.00-4.05* | 2.1 | 0.70-4.09 | 2.5 | 0.52-4.97 | 2.6 | 1.37-3.93 | 3.0 | 0.00-7.81* |
| PA          | 09/09 - 09/23/2020 | 1,341               | 11.1    | 8.85-13.71 | 18.5 | 14.40-23.51 | 4.1 | 2.38-5.87 | † | 14.8 | 12.18-17.11 | 8.6 | 5.22-12.60 | 2.5 | 0.42-4.97 | 12.3 | 9.76-15.36 | 1.7 | 0.15-3.91* |
| PR          | 09/08 - 09/15/2020 | 970                 | 3.0     | 1.78-4.27 | 3.9 | 2.00-6.30 | 2.1 | 0.82-3.70 | 2.6 | 0.50-5.34* | 2.7 | 0.62-5.24 | 3.9 | 1.32-7.18 | 2.8 | 0.61-5.67 | 3.1 | 1.90-4.49 | † |
| RI          | 09/09 - 09/24/2020 | 795                 | 2.7     | 1.15-4.91 | 3.9 | 1.05-8.15 | 1.5 | 0.54-2.69 | † | 1.7 | 0.32-3.77 | 4.1 | 1.73-6.76 | 1.6 | 0.00-3.31 | 2.7 | 1.15-4.91 | NA |
| SC          | 09/09 - 09/18/2020 | 975                 | 7.8     | 5.58-10.19 | 8.9 | 5.65-12.93 | 6.8 | 4.20-9.92 | 9.6 | 3.20-17.53 | 10.4 | 6.69-14.54 | 3.9 | 1.60-6.46 | 3.9 | 1.68-6.34 | 8.1 | 5.64-10.87 | 5.9 | 2.62-10.38 |
| SD          | 09/09 - 09/23/2020 | 99                  | 1.8     | 0.00-4.82* | † | † | † | † | † | † | † | † | † | † | † |
| TN          | 09/08 - 09/16/2020 | 1,028               | 6.7     | 4.96-8.57 | 7.4 | 4.67-10.56 | 6.0 | 3.87-8.39 | 10.8 | 7.19-15.29 | 6.8 | 3.50-10.78 | 5.8 | 3.27-9.01 | 1.7 | 0.33-3.57* | 7.1 | 5.32-9.19 | 5.3 | 2.14-9.41 |
| TX          | 09/09 - 09/24/2020 | 988                 | 8.2     | 6.16-10.47 | 7.1 | 4.15-10.37 | 9.4 | 6.27-12.66 | 12.7 | 8.35-17.62 | 8.5 | 4.72-12.60 | 5.3 | 2.68-8.60 | 1.8 | 0.31-3.75* | 9.2 | 6.86-11.50 | † |
| UT          | 09/09 - 09/18/2020 | 1,022               | 5.1     | 3.29-7.90 | 4.8 | 1.74-10.17 | 5.4 | 3.64-7.46 | † | 7.3 | 4.48-10.48 | 6.2 | 3.79-8.68 | 1.2 | 0.00-2.94* | 5.7 | 3.58-8.79 | 0.3 | 0.00-1.07* |
| VA          | 09/10 - 09/23/2020 | 1,111               | 3.2     | 1.81-5.13 | 1.4 | 0.29-3.11 | 5.0 | 2.46-8.53 | † | 4.9 | 2.67-7.62 | 1.6 | 0.27-3.19 | 1.1 | 0.20-2.26 | 3.0 | 1.49-4.94 | 4.9 | 0.86-11.21* |
| VT          | 09/09 - 09/24/2020 | 497                 | 1.7     | 0.27-4.15* | 0.8 | 0.00-1.97* | 2.7 | 0.00-7.64* | † | 0.4 | 0.00-1.59* | 0.6 | 0.00-2.24* | 2.4 | 0.00-5.68* | 0.4 | 0.00-1.82* | 2.4 | 0.25-6.11* |
| WA          | 09/09 - 09/22/2020 | 968                 | 2.5     | 1.29-3.83 | 2.9 | 1.00-5.55 | 2.0 | 0.84-3.57 | 4.2 | 0.88-8.66 | 2.2 | 0.51-4.46 | 1.1 | 0.00-2.68* | 2.5 | 0.68-4.75 | 2.7 | 1.43-4.19 | † |
| Jurisdiction | Collection Dates | Number of Specimens | Overall | Male | Female | Age <18 | Age 18-49 | Age 50-64 | Age ≥65 | Metro Counties | Non-metro Counties |
|--------------|------------------|---------------------|---------|------|--------|---------|-----------|-----------|--------|---------------|--------------------|
| WI           | 09/09 - 09/24/2020 | 976                 | 3.8     | 2.20-5.73 | 5.4     | 2.20-9.21 | 2.2     | 1.02-3.61 | †       | 3.9           | 1.85-6.26          |
|              |                  |                     |         |       |        |         |          |           |        | 2.4           | 0.65-4.44          |
|              |                  |                     |         |       |        |         |          |           |        | 3.3           | 1.37-5.73          |
|              |                  |                     |         |       |        |         |          |           |        | 4.3           | 2.12-7.11          |
|              |                  |                     |         |       |        |         |          |           |        | 2.4           | 0.71-4.76          |
| WV           | 09/09 - 09/22/2020 | 968                 | 1.3     | 0.51-2.18 | 1.8     | 0.48-3.24 | 0.8     | 0.10-1.82 | †       | 1.9           | 0.37-3.84          |
|              |                  |                     |         |       |        |         |          |           |        | 1.7           | 0.00-3.70          |
|              |                  |                     |         |       |        |         |          |           |        | 1.0           | 0.00-2.35*         |
|              |                  |                     |         |       |        |         |          |           |        | 0.5           | 0.08-1.08          |
|              |                  |                     |         |       |        |         |          |           |        | 2.5           | 0.82-4.68          |
| WY           | 09/09 - 09/24/2020 | 111                 | 1.5     | 0.00-3.97* | †       | †        | †       | †        | †       | †             | 2.3               |
|              |                  |                     |         |       |        |         |          |           |        |               | 0.00-5.76*         |

† † No specimens were collected for the subgroup in period 4. Estimates are not shown.
† Because of small cell size (n < 75) for the subgroup in period 4, estimates are not shown.
* The confidence interval surrounding the estimate is large (i.e., high variance) relative to the estimate itself (RHWCI > 1.0). Associated point estimates should be interpreted with caution.
** No positive specimens were reported for the subgroup in period 4; confidence intervals were computed separately using Clopper-Pearson Exact method.
*** No specimen records received and analyzed for the jurisdiction in period 4.
NA indicates jurisdictions that do not have non-metro counties.
Supplemental References

1. United State Census Bureau. American Community Survey Data. 2020; https://www.census.gov/programs-surveys/acs/data.html. Accessed October 7, 2020.
2. Baker R, Brick JM, Bates NA, et al. Report of the AAPOR Task Force on Non-Probability Sampling. 2013; https://www.aapor.org/AAPOR_Main/media/MainSiteFiles/NPS_TF_Report_Final_7_revised_FNL_6_22_13.pdf. Accessed October 21, 2020.
3. Iachan R, Deng Y. Weighting with propensity score matching: a national pilot survey using a mobile panel. Joint Statistical Meetings; 2017; Baltimore, Maryland.
4. Valliant R, Dever JA. Estimating Propensity Adjustments for Volunteer Web Surveys. 2011;40(1):105-137.
5. Terhanian G, Bremer J. A Smarter Way to Select Respondents for Surveys? 2012;54(6):751-780.
6. Battaglia MP, Hoaglin DC, Frankel MR. Practical Considerations in Raking Survey Data. Survey Practice 2009; https://www.surveypractice.org/article/2953-practical-considerations-in-raking-survey-data. Accessed October 21, 2020.
7. Iachan R. A new iterative method for weight trimming and raking. Joint Statistical Meetings; 2010; Vancouver, Canada.
8. Mercer A, Lau A, Kennedy C. For Weighting Online Opt-In Samples, What Matters Most? 2018; https://www.pewresearch.org/methods/2018/01/26/for-weighting-online-opt-in-samples-what-matters-most/. Accessed October 21, 2020.
9. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020; doi: 10.1001/jamaĭntermed.2020.4130.
10. Zhang F, Brick M, Kaufman S, Walter E. Variance estimation of imputed survey data. 1998; https://nces.ed.gov/pubs98/9814.pdf. Accessed October 21, 2020.
11. USAFacts. US Coronavirus Cases and Deaths. 2020; https://usafacts.org/visualizations/coronavirus-covid-19-pandemic-map. Accessed September 15, 2020.